NOVARTIS

Sponsor

Novartis Pharmaceuticals

Generic Drug Name

Dabrafenib (DRB436), LTT462, trametinib (TMT212), TNO155, LXH254, spartalizumab (PDR001), tislelizumab (VDT482)

Trial Indication(s)

Advanced or metastatic BRAF V600 colorectal cancer

Protocol Number

CADPT01C12101

Protocol Title

A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer

Clinical Trial Phase

Phase 1

Phase of Drug Development

Phase 1 (LTT462, TNO115 and LXH254), phase 3 (spartalizumab) and phase 4 (dabrafenib, trametinib and tislelizumab)

NOVARTIS

Study Start/End Dates

Study Start Date: July 22, 2020 (Actual)

Primary Completion Date: September 25, 2024 (Actual)

Study Completion Date: September 25, 2024 (Actual)

Reason for Termination (If applicable)

Novartis decided to halt recruitment of subjects to the CADPT01C12101 trial as of 13-Apr-2023 for business reasons. As a result:

- All study arms in the dose escalation portion of the trial did not enroll any new subjects as of 13-Apr-2023
- The study did not progress into the expansion phase
- Subjects who were on treatment or in screening were treated as per approved protocol

Novartis' decision to halt recruitment was not based on any safety concerns for any of the combinations in the explored indication. At the time of the decision on 13-Apr-2023, there had been 122 subjects enrolled in the dose escalation part of the study across 7 treatment arms, and treatment was ongoing in 24 subjects. Those subjects on treatment, in screening or consented, were treated as per approved protocol.

Study Design/Methodology

This was a Phase Ib, multi-center, open-label study with multiple study treatment arms. The study design consisted of a dose escalation part and could be followed by a dose expansion part for any combination study treatment arm.

Investigational drugs were considered either "backbone" or "partner". The combination of a backbone (dabrafenib + LTT462) and a partner (trametinib, LXH254, TNO155, spartalizumab or tislelizumab) constituted a triplet combination study treatment arm. The study initially enrolled subjects into the dabrafenib + LTT462 backbone arm to establish a safe dose to begin triplet combinations.

The combination of dabrafenib + trametinib served as the second backbone to which TNO155 was added as the partner, forming a triplet combination study treatment arm. Since dabrafenib + trametinib is an approved combination with established dose and safety profiles, the triplet combination dabrafenib + trametinib + TNO155 immediately entered dose escalation.

Multiple combination study treatment arms were to be enrolled in parallel during dose escalation:

- Backbone Arm 1: Dabrafenib + LTT462
- Triplet Arm 1: Dabrafenib + LTT462 in combination with trametinib
- Triplet Arm 2: Dabrafenib + LTT462 in combination with LXH254
- Triplet Arm 3: Dabrafenib + LTT462 in combination with TNO155
- Triplet Arm 4: Dabrafenib + LTT462 in combination with spartalizumab
- Triplet Arm 5: Dabrafenib + trametinib in combination with TNO155
- Triplet Arm 6: Dabrafenib + LTT462 in combination with tislelizumab

Dose escalation and determination of the maximum tolerated dose/recommended dose (MTD/RD) was guided by a Bayesian logistic regression model (BLRM) with escalation with overdose control (EWOC) criteria. Dose escalation was performed in each combination following the completion of the first cycle of study treatment. The RD was not declared for any of the treatment arms.

Dose expansion would have been initiated only after consideration of all available toxicity information, the assessment of risk to future subjects from the BLRM, and the available pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics (PD) data. The study did not progress into the expansion phase due to early termination.

Centers

18 centers in 10 countries: Germany(3), Belgium(2), Spain(3), Australia(1), Singapore(1), Israel(1), United States(4), Netherlands(1), Canada(1), United Kingdom(1)

Objectives:

The primary objective of the trial was to characterize the safety and tolerability of each study treatment arm tested and identify recommended doses (RD) and regimens for future studies.

The secondary objectives were:

- To characterize the PK of each investigational drug within each study treatment arm
- To evaluate preliminary anti-tumor activity of each study treatment arm
- To evaluate PD effect in their respective combinations in tumor

Test Product (s), Dose(s), and Mode(s) of Administration

For this study, the terms “investigational drug” or “study drug” refer to dabrafenib (DRB436), LTT462, trametinib (TMT212), LXH254, TNO155, spartalizumab (PDR001) or tislelizumab (VDT482). “Study treatment” refers to a specific combination treatment.

Dabrafenib (DRB436) was administered as oral capsules twice daily (BID) on a continuous schedule. Dose levels evaluated included 75 mg, 100 mg and 150 mg.

LTT462 was administered as oral capsules once daily (QD) continuously, with dose levels ranging from 100 mg to 400 mg.

LXH254 was administered as oral tablets BID continuously at a dose of 200 mg.

TNO155 was administered as oral capsules QD at dose levels of 20 mg and 40 mg. Two dosing regimens were explored: 3 weeks on/1 week off (3w/1w) and 2 weeks on/1 week off (2w/1w).

Trametinib (TMT212) was administered as oral tablets QD continuously at dose levels of 0.5 mg, 1 mg and 2 mg

Spartalizumab (PDR001) was administered as an intravenous (i.v.) infusion at a dose of 400 mg every 4 weeks (Q4W).

Tislelizumab (VDT482) was administered as an i.v. infusion at a dose of 300 mg Q4W.

The treatment period began on Cycle 1 Day 1. Study treatments were administered in 28-day dosing cycles for the following arms:

- Backbone Arm 1: Dabrafenib + LTT462
- Triplet Arm 1: Dabrafenib + LTT462 + Trametinib
- Triplet Arm 2: Dabrafenib + LTT462 + LXH254
- Triplet Arm 4: Dabrafenib + LTT462 + Spartalizumab
- Triplet Arm 6: Dabrafenib + LTT462 + Tislelizumab

For Triplet Arm 3 (Dabrafenib + LTT462 + TNO155) and Triplet Arm 5 (Dabrafenib + Trametinib + TNO155), treatment was administered in either:

- 28-day cycles for the TNO155 dosing schedule of 3 weeks on/1 week off (3w/1w), or
- 21-day cycles for the TNO155 dosing schedule of 2 weeks on/1 week off (2w/1w).

A subject continued study treatment until the subject experienced unacceptable toxicity, disease progression per RECIST v1.1 and/or study treatment was discontinued at the discretion of the Investigator or the subject.

Statistical Methods

A treatment group was defined by the dose level and regimen. Subjects treated with the same dose level and regimen in each combination treatment arm were defined as a treatment group and were pooled into a single treatment group.

The Safety Set (SS) was used for summaries of safety data, except for Dose-Limiting Toxicities (DLTs), for which the Dose Determining Set (DDS) was used. The SS comprised all participants who received at least one dose of study treatment. The DDS included all participants who received at least one dose of study treatment in the dose escalation, who met the minimum exposure criterion, and who had sufficient safety evaluations or experienced a DLT during the first cycle.

Safety summaries included only data from the on-treatment period, except where otherwise specified in the corresponding summary table.

Summary tables of DLTs with onset during the evaluation period (dose escalation part only) were presented by preferred term for the DDS in each study treatment.

The Best Overall Response (BOR) was summarized by treatment group for participants treated in each combination treatment arm of the dose escalation part. The BOR along with the corresponding 90% exact CI was presented. The Overall Response Rate (ORR) and Disease Control Rate (DCR) were summarized by group for participants treated in each combination treatment arm of the dose escalation part, along with the corresponding 90% exact binomial confidence interval (CI). The median Duration of Response (DOR) along with 95% CI was calculated based on the Kaplan-Meier (KM) estimates for treatments groups with at least 10 responders.

Median Progression Free Survival (PFS) with corresponding 95% CI was calculated based on KM estimates for treatment groups of ≥10 participants treated.

The PK parameters for all drugs were calculated using non-compartmental methods.

The secondary biomarker endpoint (DUSP6) included the assessment of the PD effect of the combination treatment arms in tumor.

Study Population: Key Inclusion/Exclusion Criteria

Key Inclusion Criteria:

- Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline and during on study therapy. Exceptions may be considered after documented discussion with Novartis.
- All patients must have a BRAF V600 mutation confirmed by local assessment.
- Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum with measurable disease as determined by RECIST v1.1
- Patients must have documented disease progression following, or are intolerant to, 1 or 2 lines of chemotherapy for advanced/metastatic disease

Key Exclusion Criteria:

- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in-situ cervical cancer, or other tumors that will not affect life expectancy
- Impairment of gastrointestinal function or gastrointestinal disease that may signficantly alter the absorption of study drugs
- History of or current evidence/risk of retinal verin occlusion or serous retinopathy
- History of or current interstitial lung disease or non-infectious pneumonitis
- Patients with a known history of testing positive for HIV
- Clinically significant cardiac disease at screening
- Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

– Pregnant or lactating women

Participant Flow Table

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Started	9	11	9	7	2	6	4	4	6	7
Completed	3	10	3	5	0	4	1	0	4	4
Not Completed	6	1	6	2	2	2	3	4	2	3
Death	4	0	2	0	2	1	3	2	1	1
Lost to Follow-up	1	1	0	1	0	0	0	1	0	1
NewTherapy for Study indication	0	0	1	0	0	0	0	0	0	0

Physician Decision	0	0	2	1	0	0	0	0	0	0
Subject Decision	1	0	1	0	0	1	0	1	1	1

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5, Triplet Arm 6, and All Participants in the study

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**	**Total**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	All participants

	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.		day cycles.	day cycles.	day cycles.	day cycles.	day cycles.				
Started	4	4	4	4	4	5	3	6	4	4	4	2	5	4	122
Completed	4	3	3	3	2	1	1	2	2	2	3	0	2	1	63
Not Completed	0	1	1	1	2	4	2	4	2	2	1	2	3	3	59
Death	0	1	1	0	2	4	1	2	2	1	0	1	2	3	36
Lost to Follow-up	0	0	0	1	0	0	1	1	0	0	0	0	0	0	8
NewTherapy for Study indication	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Physician Decision	0	0	0	0	0	0	0	0	0	1	1	0	1	0	6
Subject Decision	0	0	0	0	0	0	0	1	0	0	0	1	0	0	8

NOVARTIS

Baseline Characteristics

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants [units: participants]	9	11	9	7	2	6	4	4	6	7
Age Continuous (units: years) Analysis Population Type: Participants Mean ± Standard Deviation										
	57.2±7.89	62.4±15.40	64.6±8.34	54.9±12.10	65.0±1.41	48.0±8.99	55.5±13.92	60.5±5.45	46.3±9.00	55.6±15.40
Age, Customized (units: participants) Analysis Population Type: Participants Count of Participants (Not Applicable)										

18 - < 65 years	6	5	3	5	1	6	3	3	6	4
65 - < 85 years	3	5	6	2	1	0	1	1	0	3
>= 85 years	0	1	0	0	0	0	0	0	0	0
Sex: Female, Male (units: participants) Analysis Population Type: Participants Count of Participants (Not Applicable)										
Female	5	6	2	5	0	3	1	0	3	2
Male	4	5	7	2	2	3	3	4	3	5
Race/Ethnicity, Customized (units: participants) Analysis Population Type: Participants Count of Participants (Not Applicable)										
Asian	1	1	0	0	0	1	0	0	0	1
White	8	9	9	6	2	5	4	4	6	6
Missing	0	1	0	1	0	0	0	0	0	0

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5, Triplet Arm 6, and All Participants in the study

DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W	Total

	QD 3w/1w	QD 3w/1w	QD 3w/1w	QD 2w/1w	QD 2w/1w		QD 3w/1w				QD 2w/1w				
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	All participants
Number of Participants [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4	122
Age Continuous (units: years) Analysis Population Type: Participants Mean ± Standard Deviation															
	56.8±10.63	59.0±12.99	70.0±6.22	52.5±12.97	53.3±13.60	63.0±8.43	73.3±0.58	58.3±13.88	60.3±11.09	57.8±11.32	63.5±8.81	41.0±4.24	60.4±5.81	58.5±16.98	58.3±11.9
Age, Customized (units: participants)															

Analysis Population Type: Participants Count of Participants (Not Applicable)															
18 - < 65 years	3	3	1	4	3	3	0	3	3	3	2	2	3	2	77
65 - < 85 years	1	1	3	0	1	2	3	3	1	1	2	0	2	2	44
>= 85 years	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Sex: Female, Male (units: participants) Analysis Population Type: Participants Count of Participants (Not Applicable)															
Female	1	2	2	3	2	2	2	2	1	1	1	1	5	4	56
Male	3	2	2	1	2	3	1	4	3	3	3	1	0	0	66
Race/Ethnicity, Customized (units: participants) Analysis Population Type: Participants Count of Participants (Not Applicable)															
Asian	1	0	0	0	0	1	0	0	0	0	0	0	0	0	6
White	3	4	4	4	4	4	3	5	4	4	4	2	5	4	113
Missing	0	0	0	0	0	0	0	1	0	0	0	0	0	0	3

Primary Outcome Result(s)

Number of participants with AEs and SAEs during the on-treatment period

Description: Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of

	the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. The on-treatment period is defined from the day of first administration of any study treatment up to 30 days after the date of the last actual administration of any study drug.
Time Frame	Up to approximately 76 weeks
Analysis Population Description	All participants who received at least one dose of study treatment.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
Number of participants with AEs and SAEs during the	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**

on-treatment period (units: participants)	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**	**(Percentage)**
AEs	9 (100%)	11 (100%)	9 (100%)	7 (100%)	2 (100%)	6 (100%)	4 (100%)	4 (100%)	6 (100%)	7 (100%)
Treatment-related AEs	9 (100%)	11 (100%)	9 (100%)	7 (100%)	2 (100%)	6 (100%)	4 (100%)	4 (100%)	6 (100%)	7 (100%)
AEs with grade>=3	5 (55.56%)	3 (27.27%)	6 (66.67%)	3 (42.86%)	2 (100%)	3 (50%)	3 (75%)	3 (75%)	3 (50%)	4 (57.14%)
Treatment-related AEs with grade>=3	1 (11.11%)	1 (9.09%)	2 (22.22%)	2 (28.57%)	2 (100%)	1 (16.67%)	1 (25%)	2 (50%)	2 (33.33%)	2 (28.57%)
SAEs	4 (44.44%)	3 (27.27%)	6 (66.67%)	3 (42.86%)	2 (100%)	2 (33.33%)	2 (50%)	2 (50%)	3 (50%)	3 (42.86%)
Treatment-related SAEs	0 (%)	1 (9.09%)	2 (22.22%)	0 (%)	2 (100%)	0 (%)	0 (%)	1 (25%)	2 (33.33%)	1 (14.29%)
Fatal SAEs	1 (11.11%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (25%)	1 (25%)	0 (%)	0 (%)
Treatment-related fatal SAEs	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

DRB436 150mg BID + LTT462 100mg QD + TNO15	**DRB436 150mg BID + LTT462 200mg QD + TNO15**	**DRB436 150mg BID + LTT462 100mg QD + TNO15**	**DRB436 150mg BID + LTT462 100mg QD + TNO15**	**DRB436 150mg BID + LTT462 200mg QD + TNO15**	**DRB436 150mg BID + LTT462 100mg QD + PDR00**	**DRB436 150mg BID + TMT212 0.5mg QD +**	**DRB436 150mg BID + TMT212 1mg QD + TNO15**	**DRB436 150mg BID + TMT212 1mg QD + TNO15**	**DRB436 150mg BID + TMT212 1mg QD + TNO15**	**DRB436 150mg BID + TMT212 2mg QD + TNO15**	**DRB436 100mg BID + LTT462 100mg QD + VDT48**	**DRB436 150mg BID + LTT462 100mg QD + VDT48**	**DRB436 150mg BID + LTT462 200mg QD + VDT48**

	5 20mg QD 3w/1w	5 20mg QD 3w/1w	5 40mg QD 3w/1w	5 40mg QD 2w/1w	5 40mg QD 2w/1w	1 400mg Q4W	TNO15 5 20mg QD 3w/1w	5 20mg QD 3w/1w	5 20mg QD 2w/1w	5 40mg QD 2w/1w	5 20mg QD 2w/1w	2 300mg Q4W	2 300mg Q4W	2 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO15 5 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO15 5 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO15 5 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO15 5 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO15 5 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO15 5 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO15 5 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO15 5 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO15 5 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO15 5 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Number of participants with AEs and SAEs during the on-treatm	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**

ent period (units: participants)														
AEs	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	5 (100%)	3 (100%)	6 (100%)	4 (100%)	4 (100%)	4 (100%)	2 (100%)	5 (100%)	4 (100%)
Treatment-related AEs	4 (100%)	4 (100%)	4 (100%)	3 (75%)	4 (100%)	5 (100%)	3 (100%)	6 (100%)	4 (100%)	4 (100%)	4 (100%)	2 (100%)	4 (80%)	4 (100%)
AEs with grade>=3	2 (50%)	3 (75%)	2 (50%)	3 (75%)	2 (50%)	2 (40%)	0 (%)	6 (100%)	2 (50%)	3 (75%)	3 (75%)	2 (100%)	3 (60%)	3 (75%)
Treatment-related AEs with grade>=3	0 (%)	2 (50%)	2 (50%)	2 (50%)	0 (%)	0 (%)	0 (%)	2 (33.33%)	1 (25%)	2 (50%)	3 (75%)	2 (100%)	2 (40%)	3 (75%)
SAEs	1 (25%)	2 (50%)	1 (25%)	1 (25%)	3 (75%)	3 (60%)	0 (%)	4 (66.67%)	1 (25%)	3 (75%)	2 (50%)	1 (50%)	3 (60%)	2 (50%)
Treatment-related SAEs	0 (%)	2 (50%)	1 (25%)	0 (%)	2 (50%)	1 (20%)	0 (%)	1 (16.67%)	0 (%)	0 (%)	0 (%)	1 (50%)	2 (40%)	0 (%)
Fatal SAEs	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Treatment-related fatal SAEs	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

NOVARTIS

Number of participants with Dose-Limiting Toxicities (DLTs) in the first cycle

Description	A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of study treatment. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
Time Frame	First cycle of treatment (28 days or 21 days, depending on the study treatment)
Analysis Population Description	Dose-Determining Set (DDS) including all participants in the dose escalation who met the minimum exposure criterion defined in the protocol and had sufficient safety evaluations or had experienced a DLT during the first cycle.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	7	5	5	2	5	4	4	6	5
Number of participants	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**	**Count of Participant**

with Dose-Limiting Toxicities (DLTs) in the first cycle (units: participants)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)	**s** (Percentage)
At least one DLT	1 (12.5%)	0 (%)	1 (20%)	0 (%)	2 (100%)	0 (%)	0 (%)	1 (25%)	1 (16.67%)	0 (%)
Asthenia	0 (%)	0 (%)	0 (%)	0 (%)	1 (50%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Gait disturbance	0 (%)	0 (%)	0 (%)	0 (%)	1 (50%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Pain	1 (12.5%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Pancreatitis	0 (%)	0 (%)	0 (%)	0 (%)	1 (50%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Pyrexia	0 (%)	0 (%)	1 (20%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (16.67%)	0 (%)
Left ventricular dysfunction	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (25%)	0 (%)	0 (%)
Ejection fraction decreased	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Rash pruritic	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Hypersensitivity	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Hyponatraemia	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	3	3	3	3	5	3	3	4	0	5	4
Number of participants	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**	**Count of Participants**

with Dose-Limiting Toxicities (DLTs) in the first cycle (units: participants)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)	(Percentage)
At least one DLT	0 (%)	1 (33.33%)	1 (25%)	0 (%)	2 (66.67%)	0 (%)	0 (%)	2 (40%)	0 (%)	0 (%)	1 (25%)	(NaN%)	0 (%)	0 (%)
Asthenia	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Gait disturbance	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Pain	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Pancreatitis	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Pyrexia	0 (%)	1 (33.33%)	0 (%)	0 (%)	2 (66.67%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Left ventricular dysfunction	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Ejection fraction decreased	0 (%)	0 (%)	1 (25%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (25%)	(NaN%)	0 (%)	0 (%)

Rash pruritic	0 (%)	1 (33.33%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Hypersensitivity	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (20%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)
Hyponatraemia	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (20%)	0 (%)	0 (%)	0 (%)	(NaN%)	0 (%)	0 (%)

Number of participants with dose reductions and dose interruptions of dabrafenib (DRB436)

Description	Number of participants with at least one dose reduction or at least one dose interruption of dabrafenib. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Time Frame	Up to approximately 72 weeks
Analysis Population Description	All participants who received at least one dose of dabrafenib

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD;	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg

						28-day cycles.	28-day cycles.	28-day cycles.	28-day cycles.	BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
Number of participants with dose reductions and dose interruptions of dabrafenib (DRB436) (units: participants)	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**
At least one dose reduction or interruption	9 (100%)	11 (100%)	9 (100%)	7 (100%)	2 (100%)	6 (100%)	4 (100%)	4 (100%)	6 (100%)	7 (100%)
At least one dose reduction	1 (11.11%)	2 (18.18%)	0 (%)	1 (14.29%)	1 (50%)	1 (16.67%)	0 (%)	0 (%)	2 (33.33%)	0 (%)
At least one dose interruption	9 (100%)	11 (100%)	9 (100%)	7 (100%)	2 (100%)	6 (100%)	4 (100%)	4 (100%)	6 (100%)	7 (100%)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID +	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 100mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**

	LTT462 100mg QD + TNO155 20mg QD 3w/1w	LTT462 200mg QD + TNO155 20mg QD 3w/1w	LTT462 100mg QD + TNO155 40mg QD 3w/1w	LTT462 100mg QD + TNO155 40mg QD 2w/1w	LTT462 200mg QD + TNO155 40mg QD 2w/1w	LTT462 100mg QD + PDR001 400mg Q4W	TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	TMT212 1mg QD + TNO155 20mg QD 3w/1w	TMT212 1mg QD + TNO155 20mg QD 2w/1w	TMT212 1mg QD + TNO155 40mg QD 2w/1w	TMT212 2mg QD + TNO155 20mg QD 2w/1w	LTT462 100mg QD + VDT482 300mg Q4W	LTT462 100mg QD + VDT482 300mg Q4W	LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Number of participants with dose reducti	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**

ons and dose interruptions of dabrafenib (DRB436) (units: participants)														
At least one dose reduction or interruption	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	5 (100%)	3 (100%)	6 (100%)	4 (100%)	4 (100%)	4 (100%)	2 (100%)	5 (100%)	4 (100%)
At least one dose reduction	0 (%)	0 (%)	1 (25%)	0 (%)	1 (25%)	1 (20%)	0 (%)	1 (16.67%)	1 (25%)	0 (%)	1 (25%)	1 (50%)	2 (40%)	1 (25%)
At least one dose interruption	4 (100%)	4 (100%)	4 (100%)	4 (100%)	4 (100%)	5 (100%)	3 (100%)	6 (100%)	4 (100%)	4 (100%)	4 (100%)	2 (100%)	5 (100%)	4 (100%)

Number of participants with dose reductions and dose interruptions of LTT462

Description	Number of participants with at least one dose reduction or at least one dose interruption of LTT462. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Time Frame	Up to approximately 72 weeks

Analysis Population Description	All participants who received at least one dose of LTT462

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
Number of participants with dose reductions and dose interruptions of LTT462 (units:	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**

participants)										
At least one dose reduction or interruption	3 (33.33%)	7 (63.64%)	3 (33.33%)	5 (71.43%)	1 (50%)	3 (50%)	3 (75%)	2 (50%)	2 (33.33%)	3 (42.86%)
At least one dose reduction	0 (%)	2 (18.18%)	2 (22.22%)	1 (14.29%)	1 (50%)	0 (%)	1 (25%)	0 (%)	1 (16.67%)	0 (%)
At least one dose interruption	3 (33.33%)	7 (63.64%)	3 (33.33%)	5 (71.43%)	1 (50%)	3 (50%)	3 (75%)	2 (50%)	2 (33.33%)	3 (42.86%)

Triplet Arm 3, Triplet Arm 4 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	2	5	4

Number of participants with dose reductions and dose interruptions of LTT462 (units: participants)	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**
At least one dose reduction or interruption	1 (25%)	0 (%)	4 (100%)	3 (75%)	3 (75%)	5 (100%)	2 (100%)	4 (80%)	3 (75%)
At least one dose reduction	1 (25%)	0 (%)	1 (25%)	0 (%)	1 (25%)	1 (20%)	2 (100%)	1 (20%)	1 (25%)
At least one dose interruption	1 (25%)	0 (%)	4 (100%)	3 (75%)	3 (75%)	5 (100%)	2 (100%)	4 (80%)	3 (75%)

Number of participants with dose reductions and dose interruptions of trametinib (TMT212)

Description	Number of participants with at least one dose reduction or at least one dose interruption of trametinib. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Time Frame	Up to approximately 48 weeks
Analysis Population Description	All participants who received at least one dose of trametinib

Triplet Arm 3 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD +	**DRB436 150mg BID + LTT462 200mg QD +**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 200mg QD +**	**DRB436 150mg BID + TMT212 0.5mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 2mg QD +**

	TMT212 1mg QD	TMT212 1mg QD	TMT212 2mg QD	TMT212 2mg QD	TNO155 20mg QD 3w/1w	TNO155 20mg QD 3w/1w	TNO155 20mg QD 2w/1w	TNO155 40mg QD 2w/1w	TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	6	4	4	6	3	6	4	4	4
Number of participants with dose reductions and dose interruptions of trametinib (TMT212) (units: participants)	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**
At least one dose reduction or interruption	3 (50%)	3 (75%)	2 (50%)	3 (50%)	3 (100%)	3 (50%)	3 (75%)	3 (75%)	2 (50%)
At least one dose reduction	1 (16.67%)	1 (25%)	0 (%)	2 (33.33%)	0 (%)	0 (%)	2 (50%)	0 (%)	1 (25%)
At least one dose interruption	3 (50%)	3 (75%)	2 (50%)	2 (33.33%)	3 (100%)	3 (50%)	3 (75%)	3 (75%)	2 (50%)

Number of participants with dose reductions and dose interruptions of LXH254

Description	Number of participants with at least one dose reduction or at least one dose interruption of LXH254. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Time Frame	Up to approximately 31 weeks
Analysis Population Description	Up to approximately 31 weeks

Triplet Arm 2

	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	7
Number of participants with dose reductions and dose interruptions of LXH254 (units: participants)	**Count of Participants (Percentage)**
At least one dose reduction or interruption	7 (100%)
At least one dose reduction	0 (%)
At least one dose interruption	7 (100%)

Number of participants with dose reductions and dose interruptions of TNO155

Description	Number of participants with at least one dose reduction or at least one dose interruption of TNO155. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Time Frame	Up to approximately 70 weeks

Analysis Population Description	All participants who received at least one dose of TNO155

Triplet Arm 3 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	3	6	4	4	4
Number of participants with dose reductions and dose interruptions of TNO155	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**

(units: participants)										
At least one dose reduction or interruption	2 (50%)	0 (%)	3 (75%)	2 (50%)	3 (75%)	2 (66.67%)	4 (66.67%)	2 (50%)	2 (50%)	2 (50%)
At least one dose reduction	1 (25%)	0 (%)	1 (25%)	0 (%)	1 (25%)	0 (%)	1 (16.67%)	0 (%)	0 (%)	1 (25%)
At least one dose interruption	2 (50%)	0 (%)	3 (75%)	2 (50%)	3 (75%)	2 (66.67%)	4 (66.67%)	2 (50%)	2 (50%)	2 (50%)

Number of participants with dose reductions and dose interruptions of spartalizumab (PDR001)

Description	Number of participants with at least one dose reduction or at least one dose interruption of spartalizumab. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule. No dose reductions were allowed for spartalizumab.
Time Frame	Up to approximately 68 weeks
Analysis Population Description	All participants who received at least one dose of spartalizumab

Triplet Arm 4

	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W
Arm/Group Description	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	5
Number of participants with dose reductions and dose interruptions of spartalizumab (PDR001) (units: participants)	**Count of Participants (Percentage)**

At least one dose reduction or interruption	0 (%)
At least one dose reduction	0 (%)
At least one dose interruption	0 (%)

Number of participants with dose reductions and dose interruptions of tislelizumab (VDT482)

Description	Number of participants with at least one dose reduction or at least one dose interruption of tislelizumab. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule. No dose reductions were allowed for tislelizumab.
Time Frame	Up to approximately 68 weeks
Analysis Population Description	All participants who received at least one dose of tislelizumab

Triplet Arm 6

	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	2	5	4
Number of participants with dose reductions and dose interruptions of tislelizumab (VDT482) (units: participants)	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**	**Count of Participants (Percentage)**
At least one dose reduction or interruption	0 (%)	1 (20%)	2 (50%)

At least one dose reduction	0 (%)	0 (%)	0 (%)
At least one dose interruption	0 (%)	1 (20%)	2 (50%)

Dose intensity of dabrafenib (DRB436)

Description	Dose intensity of dabrafenib was calculated as cumulative actual dose in milligrams divided by duration of exposure in days.
Time Frame	Up to approximately 72 weeks
Analysis Population Description	All participants who received at least one dose of dabrafenib

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units:	9	11	9	7	2	6	4	4	6	7

participants]										
Dose intensity of dabrafenib (DRB436) (units: mg/day)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	291.43 (225.0 to 298.6)	289.29 (107.1 to 298.0)	285.33 (141.2 to 297.3)	285.48 (159.6 to 295.2)	194.15 (102.6 to 285.7)	287.99 (201.3 to 295.5)	278.89 (190.6 to 296.9)	285.81 (217.9 to 297.1)	284.74 (161.8 to 297.3)	143.18 (75.0 to 148.6)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W;	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg

	mg QD 3w/1w; 28-day cycles.	mg QD 3w/1w; 28-day cycles.	mg QD 3w/1w; 28-day cycles.	mg QD 2w/1w; 21-day cycles.	mg QD 2w/1w; 21-day cycles.	28-day cycles.	mg QD 3w/1w; 28-day cycles.	mg QD 3w/1w; 28-day cycles.	mg QD 2w/1w; 21-day cycles.	mg QD 2w/1w; 21-day cycles.	mg QD 2w/1w; 21-day cycles.	Q4W; 28-day cycles.	Q4W; 28-day cycles.	Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Dose intensity of dabrafenib (DRB436) (units: mg/day)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	290.58 (216.5 to 298.2)	287.09 (272.7 to 294.6)	224.65 (203.9 to 292.0)	276.79 (256.3 to 280.0)	254.29 (181.3 to 292.2)	219.64 (190.4 to 296.5)	285.19 (283.3 to 296.4)	278.57 (210.0 to 293.0)	273.88 (202.4 to 290.2)	273.32 (171.9 to 296.0)	286.60 (211.3 to 298.6)	92.05 (84.1 to 100.0)	284.81 (232.9 to 297.3)	251.09 (214.2 to 289.3)

Dose intensity of LTT462

Description	Dose intensity of LTT462 was calculated as cumulative actual dose in milligrams divided by duration of exposure in days.
Time Frame	Up to approximately 72 weeks
Analysis Population Description	All participants who received at least one dose of LTT462

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
Dose intensity of LTT462 (units: mg/day)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	100.00 (81.0 to 100.0)	198.28 (97.8 to 200.0)	250.00 (154.9 to 250.0)	270.97 (184.6 to 300.0)	256.03 (112.1 to 400.0)	99.11 (75.2 to 100.6)	187.43 (111.3 to 200.0)	97.50 (90.5 to 100.0)	200.00 (87.1 to 200.0)	100.00 (77.2 to 100.0)

Triplet Arm 3, Triplet Arm 4 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155	DRB436 150mg BID + LTT462 200mg QD + TNO155	DRB436 150mg BID + LTT462 100mg QD + TNO155	DRB436 150mg BID + LTT462 100mg QD + TNO155	DRB436 150mg BID + LTT462 200mg QD + TNO155	DRB436 150mg BID + LTT462 100mg QD +	DRB436 100mg BID + LTT462 100mg QD +	DRB436 150mg BID + LTT462 100mg QD +	DRB436 150mg BID + LTT462 200mg QD +

	20mg QD 3w/1w	20mg QD 3w/1w	40mg QD 3w/1w	40mg QD 2w/1w	40mg QD 2w/1w	PDR001 400mg Q4W	VDT482 300mg Q4W	VDT482 300mg Q4W	VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	2	5	4
Dose intensity of LTT462 (units: mg/day)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	100.00 (69.6 to 100.0)	200.00 (200.0 to 200.0)	78.31 (50.8 to 98.2)	93.06 (85.7 to 100.0)	180.00 (104.7 to 200.0)	78.57 (56.7 to 99.2)	53.38 (50.0 to 56.8)	94.94 (71.9 to 100.0)	171.10 (125.2 to 200.0)

Dose intensity of trametinib (TMT212)

Description	Dose intensity of trametinib was calculated as cumulative actual dose in milligrams divided by duration of exposure in days.
Time Frame	Up to approximately 48 weeks
Analysis Population Description	All participants who received at least one dose of trametinib

Triplet Arm 1 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	6	4	4	6	3	6	4	4	4
Dose intensity of trametinib (TMT212) (units: mg/day)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	0.99 (0.7 to 1.0)	0.94 (0.6 to 1.0)	1.95 (1.8 to 2.0)	1.98 (0.9 to 2.0)	0.49 (0.48 to 0.5)	0.98 (0.7 to 1.0)	0.85 (0.7 to 1.0)	0.93 (0.6 to 1.0)	1.99 (1.2 to 2.1)

Dose intensity of LXH254

Description	Dose intensity of LXH254 was calculated as cumulative actual dose in milligrams divided by duration of exposure in days.
Time Frame	Up to approximately 31 weeks
Analysis Population Description	All participants who received at least one dose of LXH254

Triplet Arm 2

	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	7
Dose intensity of LXH254 (units: mg/day)	**Median (Full Range)**
	381.82 (200.0 to 396.6)

Dose intensity of TNO155

Description	Dose intensity of TNO155 was calculated as cumulative actual dose in milligrams divided by duration of exposure in weeks.
Time Frame	Up to approximately 70 weeks
Analysis Population Description	All participants who received at least one dose of TNO155

Triplet Arm 3 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg	Triplet Arm 3: dabrafenib 150 mg	Triplet Arm 3: dabrafenib 150 mg	Triplet Arm 3: dabrafenib 150 mg	Triplet Arm 3: dabrafenib 150 mg	Triplet Arm 5: dabrafenib 150 mg	Triplet Arm 5: dabrafenib 150 mg	Triplet Arm 5: dabrafenib 150 mg	Triplet Arm 5: dabrafenib 150 mg	Triplet Arm 5: dabrafenib 150 mg

	BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	3	6	4	4	4
Dose intensity of TNO155 (units: mg/week)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	103.45 (85.1 to 106.9)	101.35 (90.6 to 108.9)	189.60 (108.6 to 208.7)	185.53 (149.3 to 188.5)	167.32 (122.5 to 196.0)	102.83 (101.1 to 106.5)	90.71 (75.4 to 108.9)	93.34 (72.0 to 98.0)	180.72 (119.3 to 191.2)	93.52 (58.7 to 98.0)

Dose intensity of spartalizumab (PDR001)

Description	Dose intensity of spartalizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and multiplied by 28 days.
Time Frame	Up to approximately 68 weeks
Analysis Population Description	All participants who received at least one dose of spartalizumab

Triplet Arm 4

	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W
Arm/Group Description	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.

Number of Participants Analyzed [units: participants]	5
Dose intensity of spartalizumab (PDR001) (units: mg/cycle (4 weeks))	**Median (Full Range)**
	400.00 (398.3 to 407.3)

Dose intensity of tislelizumab (VDT482)

Description	Dose intensity of tislelizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and multiplied by 28 days.
Time Frame	Up to approximately 68 weeks
Analysis Population Description	All participants who received at least one dose of tislelizumab

Triplet Arm 6

	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	2	5	4
Dose intensity of tislelizumab (VDT482) (units: mg/cycle (4 weeks))	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
	300.00 (300.0 to 300.0)	294.74 (282.9 to 300.0)	290.00 (243.8 to 300.0)

NOVARTIS

Secondary Outcome Result(s)

Best Overall Response (BOR) per RECIST v1.1

Description	BOR is defined as the best response recorded from the start of the study treatment until disease progression/recurrence, based on local investigator assessment per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression).
Time Frame	Up to approximately 72 weeks
Analysis Population Description	All participants who received at least one dose of study treatment.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participant	9	11	9	7	2	6	4	4	6	7

s Analyzed [units: participants]										
Best Overall Response (BOR) per RECIST v1.1 (units: participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Complete Response (CR)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Partial Response (PR)	1 (11.11%)	1 (9.09%)	0 (%)	0 (%)	0 (%)	1 (16.67%)	1 (25%)	0 (%)	0 (%)	1 (14.29%)
Stable Disease (SD)	3 (33.33%)	3 (27.27%)	3 (33.33%)	2 (28.57%)	0 (%)	2 (33.33%)	3 (75%)	3 (75%)	4 (66.67%)	1 (14.29%)
Progressive Disease (PD)	4 (44.44%)	6 (54.55%)	2 (22.22%)	5 (71.43%)	2 (100%)	3 (50%)	0 (%)	0 (%)	1 (16.67%)	3 (42.86%)
Not Evaluable (NE)	1 (11.11%)	1 (9.09%)	4 (44.44%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (25%)	1 (16.67%)	2 (28.57%)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

DRB436 150mg BID + LTT462 100mg QD +	**DRB436 150mg BID + LTT462 200mg QD +**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 200mg QD +**	**DRB436 150mg BID + LTT462 100mg QD + PDR001**	**DRB436 150mg BID + TMT212 0.5mg**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 2mg QD +**	**DRB436 100mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 200mg QD +**

	TNO155 20mg QD 3w/1w	TNO155 20mg QD 3w/1w	TNO155 40mg QD 3w/1w	TNO155 40mg QD 2w/1w	TNO155 40mg QD 2w/1w	400mg Q4W	QD + TNO155 20mg QD 3w/1w	TNO155 20mg QD 3w/1w	TNO155 20mg QD 2w/1w	TNO155 40mg QD 2w/1w	TNO155 20mg QD 2w/1w	VDT482 300mg Q4W	VDT482 300mg Q4W	VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Best Overall Response (BOR) per RECIST v1.1 (units:	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**

participants)														
Complete Response (CR)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (20%)	0 (%)
Partial Response (PR)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)	0 (%)	0 (%)	1 (25%)	0 (%)	1 (20%)	2 (50%)
Stable Disease (SD)	2 (50%)	0 (%)	2 (50%)	0 (%)	0 (%)	1 (20%)	2 (66.67%)	1 (16.67%)	0 (%)	1 (25%)	2 (50%)	0 (%)	2 (40%)	0 (%)
Progressive Disease (PD)	2 (50%)	4 (100%)	2 (50%)	2 (50%)	3 (75%)	4 (80%)	0 (%)	4 (66.67%)	3 (75%)	3 (75%)	1 (25%)	1 (50%)	1 (20%)	1 (25%)
Not Evaluable (NE)	0 (%)	0 (%)	0 (%)	2 (50%)	1 (25%)	0 (%)	0 (%)	1 (16.67%)	1 (25%)	0 (%)	0 (%)	1 (50%)	0 (%)	1 (25%)

Overall Response Rate (ORR) per RECIST v1.1

Description	ORR is the percentage of patients with a confirmed best overall response of complete response (CR) or partial response (PR), based on local investigator assessment per RECIST v1.1. For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Time Frame	Up to approximately 72 weeks
Analysis Population Description	All participants who received at least one dose of study treatment

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
Overall Response Rate (ORR) per RECIST v1.1 (units: percentage of participants)	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**
	11.1 (0.6 to 42.9)	9.1 (0.5 to 36.4)	0 (0.0 to 28.3)	0 (0.0 to 34.8)	0 (0.0 to 77.6)	16.7 (0.9 to 58.2)	25.0 (1.3 to 75.1)	0 (0.0 to 52.7)	0 (0.0 to 39.3)	14.3 (0.7 to 52.1)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Overall Response Rate	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90% Confide**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**	**Number (90%**

(ORR) per RECIST v1.1 (units: percentage of participants)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	nce Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)
	0 (0.0 to 52.7)	0 (0.0 to 52.7)	0 (0.0 to 52.7)	0 (0.0 to 52.7)	0 (0.0 to 52.7)	0 (0.0 to 45.1)	33.3 (1.7 to 86.5)	0 (0.0 to 39.3)	0 (0.0 to 52.7)	0 (0.0 to 52.7)	25.0 (1.3 to 75.1)	0 (0.0 to 77.6)	40.0 (7.6 to 81.1)	50.0 (9.8 to 90.2)

Disease Control Rate (DCR) per RECIST v1.1

Description	DCR is the percentage of patients with a best overall response of complete response (CR), partial response (PR) or stable disease (SD), based on local investigator assessment per RECIST v1.1. PR or CR per RECIST v1.1 were confirmed by a new assessment after at least 4 weeks. For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.
Time Frame	Up to approximately 72 weeks
Analysis Population Description	All participants who received at least one dose of study treatment.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1:	Backbone Arm 1:	Backbone Arm 1:	Backbone Arm 1:	Backbone Arm 1:	Triplet Arm 1:	Triplet Arm 1:	Triplet Arm 1:	Triplet Arm 1:	Triplet Arm 2:

	dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
Disease Control Rate (DCR) per RECIST v1.1 (units: percentage of participants)	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**
	44.4 (16.9 to 74.9)	36.4 (13.5 to 65.0)	33.3 (9.8 to 65.5)	28.6 (5.3 to 65.9)	0 (0.0 to 77.6)	50.0 (15.3 to 84.7)	100 (47.3 to 100)	75.0 (24.9 to 98.7)	66.7 (27.1 to 93.7)	28.6 (5.3 to 65.9)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg**	**DRB436 100mg BID + LTT462 100mg QD + VDT482**	**DRB436 150mg BID + LTT462 100mg QD + VDT482**	**DRB436 150mg BID + LTT462 200mg QD + VDT482**

	QD 3w/1w	QD 3w/1w	QD 3w/1w	QD 2w/1w	QD 2w/1w		QD 3w/1w	QD 3w/1w	QD 2w/1w	QD 2w/1w	QD 2w/1w	300mg Q4W	300mg Q4W	300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Disease Control Rate (DCR) per RECIST v1.1 (units: percentage of participants)	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**	**Number (90% Confidence Interval)**

50.0 (9.8 to 90.2)	0 (0.0 to 52.7)	50.0 (9.8 to 90.2)	0 (0.0 to 52.7)	0 (0.0 to 52.7)	20.0 (1.0 to 65.7)	100 (36.8 to 100)	16.7 (0.9 to 58.2)	0 (0.0 to 52.7)	25.0 (1.3 to 75.1)	75.0 (24.9 to 98.7)	0 (0.0 to 77.6)	80.0 (34.3 to 99.0)	50.0 (9.8 to 90.2)

Progression-Free Survival (PFS) per RECIST v1.1

Description	PFS was based on local review of tumor assessments, using RECIST 1.1 criteria. PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a subject has not had an event or received a new antineoplastic therapy, PFS was censored at the date of last adequate tumor assessment PFS was analyzed using the Kaplan-Meier method in treatment groups with at least 10 patients.
Time Frame	Up to approximately 90 weeks
Analysis Population Description	All participants who received at least one dose of study treatment.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed	9	11	9	7	2	6	4	4	6	7

[units: participants]										
Progression-Free Survival (PFS) per RECIST v1.1 (units: months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
	NA (NA to NA)[1]	1.9 (1.2 to 5.4)	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]

[1] Not estimable due to insufficient number of participants with events (n<10).

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO15	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO15	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO15	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO15	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO15	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartaliz	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD +	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD +	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD +	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD +	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD +	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizu	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizu	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizu

	5 20 mg QD 3w/1w; 28-day cycles.	5 20 mg QD 3w/1w; 28-day cycles.	5 40 mg QD 3w/1w; 28-day cycles.	5 40 mg QD 2w/1w; 21-day cycles.	5 40 mg QD 2w/1w; 21-day cycles.	umab 400 mg Q4W; 28-day cycles.	TNO15 5 20 mg QD 3w/1w; 28-day cycles.	TNO15 5 20 mg QD 3w/1w; 28-day cycles.	TNO15 5 20 mg QD 2w/1w; 21-day cycles.	TNO15 5 40 mg QD 2w/1w; 21-day cycles.	TNO15 5 20 mg QD 2w/1w; 21-day cycles.	mab 300 mg Q4W; 28-day cycles.	mab 300 mg Q4W; 28-day cycles.	mab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Progression-Free Survival (PFS) per RECIST v1.1 (units: months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]

[1] Not estimable due to insufficient number of participants with events (n<10).

Duration of Response (DOR) per RECIST v1.1

Description	DOR applies only to subjects with a BOR of CR or PR per RECIST v1.1. DOR is defined as the time from the first documented response of CR or PR to the date of the first documented progression or death due to any cause. If a participants with a CR or PR had no progression or death or received a new antineoplastic therapy, the participants was censored at the date of last adequate tumor assessment. DOR was analyzed using the Kaplan-Meier method in treatment groups with at least 10 responders.
Time Frame	Up to approximately 72 weeks

Analysis Population Description	All participants who received at least one dose of study treatment and achieved CR or PR per RECIST v1.1.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	1	1	0	0	0	1	1	0	0	1
Duration of Response (DOR) per RECIST v1.1 (units: months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**

	NA (NA to NA)[1]	NA (NA to NA)[1]						NA (NA to NA)[1]	NA (NA to NA)[1]					NA (NA to NA)[1]

[1] Not estimable due to insufficient number of participants with events (n<10).

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyze	0	0	0	0	0	0	1	0	0	0	1	0	2	2

d [units: participants]															
Duration of Response (DOR) per RECIST v1.1 (units: months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
							NA (NA to NA)[1]				NA (NA to NA)[1]		NA (NA to NA)[1]	NA (NA to NA)[1]

[1] Not estimable due to insufficient number of participants with events (n<10).

Maximum observed plasma concentration (Cmax) of dabrafenib (DRB436)

Description	Pharmacokinetic (PK) parameters were calculated based on dabrafenib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose. Dosing was omitted for dabrafenib in the evening of C1D1 (all arms), C1D14 (triplet arms 3 and 5), C1D15 (backbone arm 1, triplet arms 1 and 2) and C3D1 (triplet arms 4 and 6) to allow for a 24-hour sampling to characterize PK.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arms 3 and 5), Cycle 1 Day 15 (C1D15 – backbone arm 1, triplet arms 1 and 2) and Cycle 3 Day 1 (C3D1 – triplet arms 4 and 6): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received dabrafenib and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

DRB436 150mg BID +	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 150mg BID +**	**DRB436 75mg BID + LTT462**

	LTT462 100mg QD	LTT462 200mg QD	LTT462 250mg QD	LTT462 300mg QD	LTT462 400mg QD	LTT462 100mg QD + TMT212 1mg QD	LTT462 200mg QD + TMT212 1mg QD	LTT462 100mg QD + TMT212 2mg QD	LTT462 200mg QD + TMT212 2mg QD	100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	10	8	7	2	6	4	4	6	7
Maximum observed plasma concentration (Cmax) of dabrafenib (DRB436) (units: ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=8,10,7,7,2,6,4,4,4,6)	1330 (82.3 %)	1570 (69.1 %)	1680 (56.9 %)	1380 (49.9 %)	2050 (29.4 %)	2890 (82.5 %)	943 (293.8 %)	2670 (26.5 %)	2130 (98.9 %)	1360 (40.0 %)
C1D14, C1D15 or C3D1, as applicable (n=8,8,6,6,1,5,4,4,5,6)	2220 (44.0 %)	1830 (25.9 %)	2190 (50.6 %)	1440 (40.2 %)	1450	1990 (61.3 %)	979 (74.7 %)	2310 (48.5 %)	1120 (67.9 %)	1620 (54.2 %)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	5	3	6	4	4	4	2	5	4
Maximum observed plasma concentration	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**

(Cmax) of dabrafenib (DRB436) (units: ng/mL)	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**
C1D1 (n=4,3,3,4,3,5,3,5,4,4,4,2,5,4)	1910 (28.8%)	3700 (49.6%)	4380 (53.5%)	2490 (65.8%)	1960 (92.8%)	2530 (3 0.3%)	3940 (53.8%)	3050 (61.3%)	2310 (44.1%)	2220 (28.6%)	1650 (96.8%)	1280 (87.4%)	1960 (28.3%)	1810 (38.6%)
C1D14, C1D15 or C3D1, as applicable (n=3,1,3,2,2,2,1,5,4,3,4,0,3,2)	1750 (95.9%)	2960	2130 (52.6%)	2540 (54.7%)	2700 (38.7%)	3000 (9 .0%)	2930	2290 (39.5%)	1510 (51.7%)	2100 (28.7%)	1820 (46.9%)		2340 (17.2%)	792 (1 42.8%)

Time to maximum observed plasma concentration (Tmax) of dabrafenib (DRB436)

Description	PK parameters were calculated based on dabrafenib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters. Dosing was omitted for dabrafenib in the evening of C1D1 (all arms), C1D14 (triplet arms 3 and 5), C1D15 (backbone arm 1, triplet arms 1 and 2) and C3D1 (triplet arms 4 and 6) to allow for a 24-hour sampling to characterize PK.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arms 3 and 5), Cycle 1 Day 15 (C1D15 – backbone arm 1, triplet arms 1 and 2) and Cycle 3 Day 1 (C3D1 – triplet arms 4 and 6): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received dabrafenib and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 200mg QD +**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 200mg QD +**	**DRB436 75mg BID + LTT462 100mg QD + LXH254**

						TMT212 1mg QD	TMT212 1mg QD	TMT212 2mg QD	TMT212 2mg QD	200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	10	8	7	2	6	4	4	6	7
Time to maximum observed plasma concentration (Tmax) of dabrafenib (DRB436) (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
C1D1 (n=8,10,7,7,2,6,4,4,4,6)	2.05 (0.967 to 20.1)	2.03 (1.02 to 4.20)	2.07 (1.08 to 3.70)	2.02 (1.08 to 4.07)	1.58 (1.10 to 2.05)	1.88 (1.03 to 2.03)	2.79 (1.93 to 7.83)	1.54 (1.07 to 2.02)	1.23 (1.02 to 2.00)	1.08 (0.967 to 2.12)
C1D14, C1D15 or C3D1, as applicable (n=8,8,6,6,1,5,4,4,5,6)	1.68 (1.08 to 2.10)	2.03 (1.00 to 2.10)	1.53 (1.00 to 2.17)	1.51 (1.00 to 4.17)	1.08 (1.08 to 1.08)	1.97 (1.08 to 3.33)	0.992 (0.80 to 1.92)	1.12 (1.00 to 1.95)	1.17 (0.983 to 2.57)	1.04 (1.00 to 1.07)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT46	DRB436 150mg BID + LTT46	DRB436 150mg BID + LTT46	DRB436 150mg BID + LTT46	DRB436 150mg BID + LTT46	DRB436 150mg BID + LTT462 100mg QD +	DRB436 150mg BID + TMT2	DRB436 150mg BID + TMT2	DRB436 150mg BID + TMT2	DRB436 150mg BID + TMT2	DRB436 150mg BID + TMT2	DRB436 100mg BID + LTT462	DRB436 150mg BID + LTT462	DRB436 150mg BID + LTT462

	2 100mg QD + TNO155 20mg QD 3w/1w	2 200mg QD + TNO155 20mg QD 3w/1w	2 100mg QD + TNO155 40mg QD 3w/1w	2 100mg QD + TNO155 40mg QD 2w/1w	2 200mg QD + TNO155 40mg QD 2w/1w	PDR001 400mg Q4W	12 0.5mg QD + TNO155 20mg QD 3w/1w	12 1mg QD + TNO155 20mg QD 3w/1w	12 1mg QD + TNO155 20mg QD 2w/1w	12 1mg QD + TNO155 40mg QD 2w/1w	12 2mg QD + TNO155 20mg QD 2w/1w	100mg QD + VDT482 300mg Q4W	100mg QD + VDT482 300mg Q4W	200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	5	3	6	4	4	4	2	5	4
Time to maximum observed plasma concentration (Tmax) of dabrafenib (DRB436) (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**

C1D1 (n=4,3,3,4,3,5,3,5,4,4,4,2,5,4)	2.03 (1.93 to 4.00)	1.95 (1.05 to 2.08)	1.00 (1.00 to 2.20)	1.55 (1.05 to 2.25)	2.15 (2.00 to 2.17)	2.00 (0.867 to 4.25)	1.97 (1.12 to 2.05)	2.00 (1.00 to 2.07)	1.31 (1.07 to 1.95)	1.50 (1.03 to 2.03)	1.98 (1.02 to 4.00)	1.53 (1.08 to 1.97)	2.05 (1.88 to 2.20)	2.66 (1.95 to 4.00)
C1D14, C1D15 or C3D1, as applicable (n=3,1,3,2,2,2,1,5,4,3,4,0,3,2)	1.08 (1.00 to 3.52)	1.02 (1.02 to 1.02)	1.13 (1.05 to 1.92)	1.60 (1.07 to 2.13)	1.58 (1.08 to 2.08)	1.04 (1.00 to 1.08)	2.08 (2.08 to 2.08)	1.12 (1.08 to 2.17)	1.04 (0.517 to 1.08)	1.07 (1.05 to 2.08)	1.13 (1.02 to 1.67)		2.00 (1.13 to 2.12)	1.06 (1.03 to 1.08)

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of dabrafenib (DRB436)

Description	PK parameters were calculated based on dabrafenib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation. Dosing was omitted for dabrafenib in the evening of C1D1 (all arms), C1D14 (triplet arms 3 and 5), C1D15 (backbone arm 1, triplet arms 1 and 2) and C3D1 (triplet arms 4 and 6) to allow for a 24-hour sampling to characterize PK.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arms 3 and 5), Cycle 1 Day 15 (C1D15 – backbone arm 1, triplet arms 1 and 2) and Cycle 3 Day 1 (C3D1 – triplet arms 4 and 6): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received dabrafenib and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib	Backbone Arm 1: dabrafenib	Backbone Arm 1: dabrafenib	Backbone Arm 1: dabrafenib	Backbone Arm 1: dabrafenib	Triplet Arm 1: dabrafenib	Triplet Arm 1: dabrafenib	Triplet Arm 1: dabrafenib	Triplet Arm 1: dabrafenib	Triplet Arm 2: dabrafenib

	150 mg BID + LTT462 100 mg QD; 28-day cycles.	150 mg BID + LTT462 200 mg QD; 28-day cycles.	150 mg BID + LTT462 250 mg QD; 28-day cycles.	150 mg BID + LTT462 300 mg QD; 28-day cycles.	150 mg BID + LTT462 400 mg QD; 28-day cycles.	150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	10	8	7	2	6	4	4	6	7
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of dabrafenib (DRB436) (units: h*ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=8,10,7,7,2,6,4,4,4,6)	9110 (37.6 %)	11900 (60.0%)	10400 (96.4%)	8960 (45.9 %)	7990 (63.1 %)	12900 (76.3%)	6080 (78.0 %)	11900 (11.9%)	11000 (46.4%)	5870 (30.0 %)
C1D14, C1D15 or C3D1, as applicable (n=8,8,6,6,1,5,4,4,5,6)	8080 (42.0 %)	6960 (27.1 %)	10100 (62.1%)	8740 (49.9 %)	6760	9300 (70.4 %)	4700 (33.1 %)	10200 (52.2%)	5540 (22.5 %)	5500 (59.8 %)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

DRB436 150mg	**DRB436 150mg**	**DRB436 150mg**	**DRB436 150mg**	**DRB436 150mg**	**DRB436 150mg**	**DRB436 150mg**	**DRB436 150mg**	**DRB436 150m**	**DRB436 150mg**	**DRB436 150m**	**DRB436 100m**	**DRB436 150mg**	**DRB436 150m**

	BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	BID + LTT462 100mg QD + PDR001 400mg Q4W	BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	g BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	g BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w	g BID + LTT462 100mg QD + VDT482 300mg Q4W	BID + LTT462 100mg QD + VDT482 300mg Q4W	g BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO1 55 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO1 55 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	5	3	6	4	4	4	2	5	4
Area under the plasma concentration -time curve from time	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geom**	**Geometric Mean (Geo**	**Geometric Mean (Geom**	**Geometric Mean (Geo**	**Geometric Mean (Geo**	**Geometric Mean (Geom**	**Geometric Mean (Geo**

zero to the time of the last quantifiable concentration (AUClast) of dabrafenib (DRB436) (units: h*ng/mL)	etric Coefficient of Variation)	etric Coefficient of Variation)	etric Coefficient of Variation)	etric Coefficient of Variation)	etric Coefficient of Variation)	etric Coefficient of Variation)	etric Coefficient of Variation)	etric Coefficient of Variation)	metric Coefficient of Variation)	etric Coefficient of Variation)	metric Coefficient of Variation)	metric Coefficient of Variation)	etric Coefficient of Variation)	metric Coefficient of Variation)
C1D1 (n=4,3,3,4,3,5, 3,5,4,4,4,2,5,4)	12400 (19.0%)	17900 (17.6%)	16100 (87.5%)	12300 (39.6%)	11400 (92.7%)	14900 (20.9%)	17300 (121.5%)	13900 (20.4%)	9420 (25.8%)	8740 (3 3.7%)	9930 (58.5%)	4660 (61.8%)	11600 (20.0%)	9860 (35.4%)
C1D14, C1D15 or C3D1, as applicable (n=3,1,3,2,2,2, 1,5,4,3,4,0,3,2)	6030 (7 3.9%)	9710	15300 (29.2%)	8750 (3 6.7%)	13800 (6.5%)	7160 (1 9.6%)	14800	9210 (1 2.5%)	6940 (67.1%)	9290 (1 08.6%)	6190 (38.6%)		6650 (2 3.0%)	3920 (73.8%)

Maximum observed plasma concentration (Cmax) of LTT462

Description	PK parameters were calculated based on LTT462 plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arm 3), Cycle 1 Day 15 (C1D15 – backbone arm 1, triplet arms 1 and 2) and Cycle 3 Day 1 (C3D1 – triplet arms 4 and 6): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received LTT462 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

DRB436 150mg BID + LTT462	DRB436 150mg BID + LTT462	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 75mg BID + LTT462 100mg QD +

	100mg QD	200mg QD				+ TMT212 1mg QD	+ TMT212 1mg QD	+ TMT212 2mg QD	+ TMT212 2mg QD	LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	10	8	7	2	6	4	4	6	7
Maximum observed plasma concentration (Cmax) of LTT462 (units: ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=8,10,7,7,2,6,4,4,4,6)	193 (82.1 %)	533 (99.0 %)	577 (79.7%)	881 (114.1 %)	1490 (35.7 %)	263 (316.0 %)	480 (44.4 %)	124 (139.1 %)	437 (146.9 %)	289 (74.3 %)
C1D14, C1D15 or C3D1, as applicable (n=8,8,6,6,1,5,4,4,5,4)	385 (37.5 %)	816 (49.7 %)	1000 (251.3 %)	1520 (71.9 %)	2050	269 (286.4 %)	550 (127.5 %)	328 (56.0 %)	781 (60.2 %)	700 (44.1 %)

Triplet Arm 3, Triplet Arm 4, and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	5	2	5	4
Maximum observed plasma concentration (Cmax) of LTT462 (units: ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=4,2,3,4,3,5,2,5,4)	115 (112.7%)	1100 (44.4%)	254 (41.4%)	322 (142.3%)	597 (81.5%)	376 (75.8%)	739 (12.0%)	276 (82.8%)	738 (74.6%)
C1D14, C1D15 or C3D1, as applicable (n=3,1,3,2,2,2,0,3,2)	170 (307.8%)	1330	555 (45.2%)	452 (73.6%)	1750 (9.3%)	274 (47.0%)		396 (31.0%)	925 (8.5%)

Time to maximum observed plasma concentration (Tmax) of LTT462

Description	PK parameters were calculated based on LTT462 plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arm 3), Cycle 1 Day 15 (C1D15 – backbone arm 1, triplet arms 1 and 2) and Cycle 3 Day 1 (C3D1 – triplet arms 4 and 6): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received LTT462 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	10	8	7	2	6	4	4	6	7

Time to maximum observed plasma concentration (Tmax) of LTT462 (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
C1D1 (n=8,10,7,7,2,6,4,4,4,6)	4.05 (2.03 to 23.2)	2.05 (1.02 to 4.20)	3.93 (1.08 to 24.0)	7.53 (2.02 to 8.08)	3.09 (2.07 to 4.12)	2.02 (1.75 to 3.88)	3.68 (2.00 to 7.83)	2.03 (1.02 to 8.00)	3.12 (1.42 to 4.23)	2.06 (1.05 to 24.0)
C1D14, C1D15 or C3D1, as applicable (n=8,8,6,6,1,5,4,4,5,4)	2.08 (1.08 to 3.83)	2.07 (1.00 to 4.13)	3.92 (1.02 to 23.0)	3.02 (1.00 to 4.17)	2.05 (2.05 to 2.05)	2.28 (2.05 to 4.02)	2.84 (0.983 to 4.05)	1.95 (1.07 to 7.97)	2.08 (0.983 to 4.30)	2.08 (2.00 to 2.20)

Triplet Arm 3, Triplet Arm 4, and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.

Number of Participants Analyzed [units: participants]	4	3	4	4	4	5	2	5	4
Time to maximum observed plasma concentration (Tmax) of LTT462 (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
C1D1 (n=4,2,3,4,3,5,2,5,4)	3.03 (2.00 to 4.13)	2.43 (1.05 to 3.80)	2.20 (1.00 to 4.08)	2.99 (1.08 to 4.05)	2.17 (2.00 to 8.00)	2.00 (1.95 to 6.08)	2.96 (2.08 to 3.83)	2.20 (2.05 to 6.62)	3.05 (1.95 to 7.47)
C1D14, C1D15 or C3D1, as applicable (n=3,1,3,2,2,2,0,3,2)	2.05 (2.00 to 3.52)	1.95 (1.95 to 1.95)	1.92 (1.13 to 2.08)	2.94 (2.13 to 3.75)	4.03 (3.88 to 4.17)	2.45 (1.00 to 3.90)		2.08 (2.00 to 4.07)	2.94 (2.08 to 3.80)

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of LTT462

Description	PK parameters were calculated based on LTT462 plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arm 3), Cycle 1 Day 15 (C1D15 – backbone arm 1, triplet arms 1 and 2) and Cycle 3 Day 1 (C3D1 – triplet arms 4 and 6): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received LTT462 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD +**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254**

								TMT212 2mg QD		200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	8	10	8	7	2	6	4	4	6	7
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of LTT462 (units: h*ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=8,10,7,7,2,6,4,4,4,6)	2440 (65.6%)	5900 (42.6%)	7370 (133.9%)	11600 (119.4%)	13000 (37.3%)	2740 (329.0%)	5660 (52.5%)	1300 (75.5%)	4730 (116.7%)	2700 (91.1%)
C1D14, C1D15 or C3D1, as applicable (n=8,8,6,6,1,5,4,4,5,4)	4700 (42.6%)	8280 (53.7%)	10400 (246.4%)	18100 (74.1%)	16500	2850 (273.3%)	7180 (100.0%)	3730 (54.5%)	6720 (83.4%)	6770 (27.3%)

Triplet Arm 3, Triplet Arm 4, and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	5	2	5	4
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of LTT462 (units: h*ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**

C1D1 (n=4,2,3,4,3,5,2,5,4)	1080 (112.6 %)	10200 (0.0 %)	2310 (24.4 %)	3350 (141.2 %)	6200 (52.3 %)	3660 (54.8%)	4150 (1.9%)	2840 (93.7 %)	7750 (58.2 %)
C1D14, C1D15 or C3D1, as applicable (n=3,1,3,2,2,2,0,3,2)	1590 (179.5 %)	13600	7420 (7.4%)	6070 (42.3%)	22800 (9.0 %)	2900 (61.9%)		3530 (10.3 %)	8930 (1.6%)

Maximum observed plasma concentration (Cmax) of trametinib (TMT212)

Description	PK parameters were calculated based on trametinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arm 5), and Cycle 1 Day 15 (C1D15 – triplet arm 1): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received trametinib and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 1 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**
Arm/Group Description	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD;	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD

	28-day cycles.	28-day cycles.	28-day cycles.	28-day cycles.	3w/1w; 28-day cycles.	3w/1w; 28-day cycles.	2w/1w; 21-day cycles.	2w/1w; 21-day cycles.	2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	6	4	4	6	3	6	4	4	4
Maximum observed plasma concentration (Cmax) of trametinib (TMT212) (units: ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=6,4,4,4,3,5,4,4,4)	2.74 (84.2%)	2.06 (61.5%)	3.09 (77.3%)	1.61 (21.9%)	2.33 (28.9%)	2.88 (89.6%)	3.24 (106.4%)	3.37 (20.8%)	6.78 (27.3%)
C1D14 or C1D15, as applicable (n=5,4,4,5,1,5,4,3,4)	9.92 (51.4%)	8.60 (48.6%)	20.5 (33.8%)	18.3 (32.7%)	9.19	10.0 (36.5%)	10.5 (31.0%)	10.4 (6.8%)	24.0 (26.3%)

Time to maximum observed plasma concentration (Tmax) of trametinib (TMT212)

Description	PK parameters were calculated based on trametinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arm 5), and Cycle 1 Day 15 (C1D15 – triplet arm 1): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received trametinib and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 1 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	6	4	4	6	3	6	4	4	4
Time to maximum observed plasma concentration (Tmax) of trametinib (TMT212) (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
C1D1 (n=6,4,4,4,3,5,4,4,4)	1.06 (1.00 to 24.7)	1.97 (1.00 to 2.00)	1.54 (1.07 to 4.00)	3.06 (1.02 to 8.00)	2.05 (0.983 to 2.10)	1.17 (1.00 to 2.07)	1.07 (0.533 to 1.95)	1.04 (1.00 to 1.97)	1.13 (1.02 to 1.85)
C1D14 or C1D15, as applicable (n=5,4,4,5,1,5,4,3,4)	1.22 (1.00 to 3.33)	1.94 (1.88 to 3.50)	1.53 (1.00 to 3.72)	1.17 (0.983 to 2.08)	1.05 (1.05 to 1.05)	1.12 (1.08 to 1.28)	1.48 (0.517 to 2.12)	1.07 (1.05 to 2.07)	1.36 (1.02 to 2.28)

NOVARTIS

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of trametinib (TMT212)

Description	PK parameters were calculated based on trametinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time Frame	Cycle 1 Day 1 (C1D1– all arms), Cycle 1 Day 14 (C1D14 – triplet arm 5), and Cycle 1 Day 15 (C1D15 – triplet arm 1): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received trametinib and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 1 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	6	4	4	6	3	6	4	4	4
Area under the plasma	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**	**Geometric Mean**

concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of trametinib (TMT212) (units: h*ng/mL)	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**	**(Geometric Coefficient of Variation)**
C1D1 (n=6,4,4,4,3,5,4,4,4)	22.9 (39.9%)	19.9 (42.1%)	33.6 (25.1%)	25.1 (24.0%)	16.9 (33.4%)	25.6 (47.7%)	21.4 (60.0%)	23.1 (36.2%)	51.8 (14.8%)
C1D14 or C1D15, as applicable (n=5,4,4,5,1,5,4,3,4)	145 (35.1%)	146 (33.5%)	316 (20.0%)	217 (35.0%)	134	148 (37.0%)	124 (101.9%)	137 (3.2%)	254 (29.1%)

Maximum observed plasma concentration (Cmax) of LXH254

Description	PK parameters were calculated based on LXH254 plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose. Dosing was omitted for LXH254 in the evening of C1D1 and C1D15 to allow for a 24-hour sampling to characterize PK.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received LXH254 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 2

	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	7

Maximum observed plasma concentration (Cmax) of LXH254 (units: ng/mL)	**Geometric Mean** **(Geometric Coefficient of Variation)**
C1D1 (n=6)	675 (100.0%)
C1D15 (n=4)	1960 (510%)

Time to maximum observed plasma concentration (Tmax) of LXH254

Description	PK parameters were calculated based on LXH254 plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters. Dosing was omitted for LXH254 in the evening of C1D1 and C1D15 to allow for a 24-hour sampling to characterize PK.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received LXH254 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 2

	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	7
Time to maximum observed plasma concentration (Tmax) of LXH254 (units: hours)	**Median** **(Full Range)**
C1D1 (n=6)	3.93 (1.97 to 24.0)
C1D15 (n=4)	2.12 (2.00 to 4.30)

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of LXH254

Description	PK parameters were calculated based on LXH254 plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received LXH254 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 2

	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	7
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of LXH254 (units: h*ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=6)	8280 (133.3%)
C1D15 (n=4)	22000 (15.6%)

Maximum observed plasma concentration (Cmax) of TNO155

Description	PK parameters were calculated based on TNO155 plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 1 Day 14 (C1D14): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received TNO155 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 3 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	3	6	4	4	4
Maximum observed plasma concentration (Cmax) of TNO155 (units: ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=4,3,3,4,3,3,5,4,4,4)	62.4 (23.1 %)	84.4 (34.3 %)	204 (29.7 %)	158 (36.0 %)	150 (5.9%)	83.4 (21.5 %)	69.7 (49.4 %)	72.4 (32.8 %)	190 (18.5 %)	75.0 (22.8 %)

C1D14 (n=3,1,3,2,2,1,5,4,3,4)	118 (53.8 %)	57.0	297 (23.2 %)	228 (66.1 %)	251 (29.8 %)	119	100 (39.1 %)	97.4 (24.2 %)	256 (30.8 %)	107 (33.9 %)

Time to maximum observed plasma concentration (Tmax) of TNO155

Description	PK parameters were calculated based on TNO155 plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 1 Day 14 (C1D14): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received TNO155 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 3 and Triplet Arm 5

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-

	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.	day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	3	6	4	4	4
Time to maximum observed plasma concentration (Tmax) of TNO155 (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
C1D1 (n=4,3,3,4,3,3,5,4,4,4)	2.00 (1.00 to 4.00)	1.08 (1.05 to 1.95)	1.00 (1.00 to 2.18)	1.55 (1.05 to 8.08)	2.15 (1.02 to 3.82)	1.00 (0.983 to 3.83)	2.00 (1.00 to 2.15)	1.07 (0.533 to 1.95)	1.03 (1.00 to 2.05)	1.15 (1.02 to 2.12)
C1D14 (n=3,1,3,2,2,1,5,4,3,4)	3.52 (2.00 to 8.00)	1.02 (1.02 to 1.02)	2.08 (0.933 to 2.10)	3.18 (2.12 to 4.23)	3.13 (2.08 to 4.17)	1.05 (1.05 to 1.05)	1.17 (1.08 to 2.17)	1.49 (0.517 to 1.95)	1.07 (1.05 to 2.07)	1.43 (1.05 to 4.08)

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of TNO155

Description	PK parameters were calculated based on TNO155 plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 1 Day 14 (C1D14): pre-dose, 1, 2, 4, 8 and 24 hours post-dose.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received TNO155 and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 3 and Triplet Arm 5

DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg**	**DRB436 150mg BID + LTT462 100mg QD**	**DRB436 150mg BID + LTT462 100mg QD**	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + TMT212 0.5mg**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 1mg QD +**	**DRB436 150mg BID + TMT212 2mg QD +**

	+ TNO155 20mg QD 3w/1w	QD + TNO155 20mg QD 3w/1w	+ TNO155 40mg QD 3w/1w	+ TNO155 40mg QD 2w/1w	+ TNO155 40mg QD 2w/1w	QD + TNO155 20mg QD 3w/1w	TNO155 20mg QD 3w/1w	TNO155 20mg QD 2w/1w	TNO155 40mg QD 2w/1w	TNO155 20mg QD 2w/1w
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.
Number of Participants Analyzed [units: participants]	4	3	4	4	4	3	6	4	4	4
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of TNO155 (units: h*ng/mL)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=4,3,3,4,3,3,5,4,4,4)	817 (14.2%)	987 (41.1%)	2240 (23.6%)	2190 (41.8%)	1990 (20.6%)	843 (12.6%)	857 (33.7%)	619 (24.6%)	1850 (39.3%)	829 (6.9%)
C1D14 (n=3,1,3,2,2,1,5,4,3,4)	1660 (39.3%)	535	3600 (37.1%)	3680 (65.3%)	4640 (27.9%)	1360	1360 (52.2%)	906 (103.1%)	2980 (27.5%)	1110 (33.7%)

Maximum observed serum concentration (Cmax) of spartalizumab (PDR001)

Description	PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 3 Day 1 (C3D1): pre-infusion, end of infusion, 168 hours (only C1D1), 336 hours and 672 hours after end of infusion.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received spartalizumab and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 4

	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W
Arm/Group Description	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	5
Maximum observed serum concentration (Cmax) of spartalizumab (PDR001) (units: µg/mL)	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=5)	106 (20.5%)
C3D1 (n=2)	132 (8.0%)

Time to maximum observed serum concentration (Tmax) of spartalizumab (PDR001)

Description	PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 3 Day 1 (C3D1): pre-infusion, end of infusion, 168 hours (only C1D1), 336 hours and 672 hours after end of infusion.

Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received spartalizumab and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 4

	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W
Arm/Group Description	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	5
Time to maximum observed serum concentration (Tmax) of spartalizumab (PDR001) (units: hours)	**Median (Full Range)**
C1D1 (n=5)	0.60 (0.517 to 0.683)
C3D1 (n=2)	0.567 (0.517 to 0.617)

Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of spartalizumab (PDR001)

Description	PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 3 Day 1 (C3D1): pre-infusion, end of infusion, 168 hours (only C1D1), 336 hours and 672 hours after end of infusion.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received spartalizumab and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 4

	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W
Arm/Group Description	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	5
Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of spartalizumab (PDR001) (units: h*µg/mL)	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=5)	26300 (28.5%)
C3D1 (n=2)	46700 (31.5%)

Maximum observed serum concentration (Cmax) of tislelizumab (VDT482)

Description	PK parameters were calculated based on tislelizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 3 Day 1 (C3D1): pre-infusion, end of infusion, 24 hours (only C1D1), 168 hours (only C1D1), 336 hours and 672 hours after end of infusion.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received tislelizumab and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 6

	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W
Arm/Group Description	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	2	5	4

Maximum observed serum concentration (Cmax) of tislelizumab (VDT482) (units: ng/ml)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=2,5,4)	97900 (30.7%)	72900 (21.3%)	103000 (47.8%)
C3D1 (n=0,3,1)		110000 (13.7%)	143000

Time to maximum observed serum concentration (Tmax) of tislelizumab (VDT482)

Description	PK parameters were calculated based on tislelizumab serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 3 Day 1 (C3D1): pre-infusion, end of infusion, 24 hours (only C1D1), 168 hours (only C1D1), 336 hours and 672 hours after end of infusion.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received tislelizumab and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 6

	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	2	5	4
Time to maximum observed serum concentration (Tmax) of tislelizumab (VDT482) (units: hours)	**Median (Full Range)**	**Median (Full Range)**	**Median (Full Range)**
C1D1 (n=2,5,4)	1.07 (1.05 to 1.08)	19.8 (1.17 to 24.1)	1.11 (1.02 to 24.1)

C3D1 (n=0,3,1)	0.750 (0.60 to 1.08)	0.667 (0.667 to 0.667)

Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of tislelizumab (VDT482)

Description	PK parameters were calculated based on tislelizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time Frame	Cycle 1 Day 1 (C1D1) and Cycle 3 Day 1 (C3D1): pre-infusion, end of infusion, 24 hours (only C1D1), 168 hours (only C1D1), 336 hours and 672 hours after end of infusion.
Analysis Population Description	Participants in the pharmacokinetic analysis set (PAS) who received tislelizumab and had an available value for the outcome measure. PAS consisted of all participants who provided an evaluable PK profile.

Triplet Arm 6

	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	2	5	4
Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of tislelizumab (VDT482) (units: h*ng/ml)	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**	**Geometric Mean (Geometric Coefficient of Variation)**
C1D1 (n=2,5,4)	21300000 (37.5%)	22500000 (16.3%)	22800000 (54.6%)
C3D1 (n=0,3,1)		44800000 (30.9%)	52700000

Percent change from baseline of DUSP6 in tumor tissue

Description	During dose escalation, quantitative polymerase chain reaction (qPCR) was used to assess levels of DUSP6 mRNA in baseline and on-treatment tumor biopsies.
Time Frame	Baseline (screening), post-baseline (during cycle 1). The duration of each cycle was 28 or 21 days, depending on the dosing schedule.
Analysis Population Description	Participants who received at least one dose of study treatment and had a valid assessment of DUSP6 expression in tumor samples at both baseline and post-baseline.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	**DRB436 150mg BID + LTT462 200mg QD**	**DRB436 150mg BID + LTT462 250mg QD**	**DRB436 150mg BID + LTT462 300mg QD**	**DRB436 150mg BID + LTT462 400mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	3	0	1	1	1	2	0	2	0
Percent change from baseline of	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**	**Mean ±**

DUSP6 in tumor tissue (units: percent change from baseline)	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**	**Standard Deviation**
	-51.40 ± 10.034	-20.14 ± 59.545		-56.66	2.31	-25.06	-75.37 ± 12.009		-17.90 ± 66.049	

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w;	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w;	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w;	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w;	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w;	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w;	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w;	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w;	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w;	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w;	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W;	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W;	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W;

	28-day cycles.	28-day cycles.	28-day cycles.	21-day cycles.	21-day cycles.		28-day cycles.	28-day cycles.	21-day cycles.	21-day cycles.	21-day cycles.	28-day cycles.	28-day cycles.	28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	1	1	1	2	0	1	2	2	2	0	1	0
Percent change from baseline of DUSP6 in tumor tissue (units: percent change from baseline)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
	-42.59 ± 31.588	-46.07 ± 17.455	-13.06	-67.47	-86.98	-49.18 ± 18.946		-26.22	-75.80 ± 9.302	-38.25 ± 40.238	-88.52 ± 10.670		134.44	

Post-Hoc Outcome Result(s)

All-Collected Deaths

ContinDescription Deaths in the on-treatment and post-treatment safety follow-up (FU) were collected from the first dose of study treatment through 30 days after the last dose of dabrafenib, LTT462, trametinib, LXH254, or TNO155; 150 days after the last dose of spartalizumab; and 120 days after the last dose of tislelizumab, whichever was longer.
Deaths in the disease progression FU period were collected from 31 days after the last dose of dabrafenib, LTT462, trametinib, LXH254, or TNO155; 151 days after the last dose of spartalizumab; and 121 days after the last dose of tislelizumab, until the end of study. All deaths

	refer to the combined total of on-treatment and post-treatment safety follow-up (FU) deaths, as well as deaths in the disease progression FU.
Time Frame	On-treatment and post-treatment safety FU deaths: up to approximately 90 weeks. Disease progression FU deaths: up to approximately 90 weeks.
Analysis Population Description	All participants who received at least one dose of study treatment.

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD	DRB436 150mg BID + LTT462 200mg QD	DRB436 150mg BID + LTT462 250mg QD	DRB436 150mg BID + LTT462 300mg QD	DRB436 150mg BID + LTT462 400mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Number of Participants Analyzed [units: participants]	9	11	9	7	2	6	4	4	6	7
On-treatment and post-treatment safety FU	2	0	1	0	1	1	1	1	0	1

deaths (n=9,11,9,7 ,2,6,4,4,6,7)										
Disease progression FU deaths (n=7,11,8,7 ,1,5,3,3,6,6)	2	1	1	0	1	0	2	2	0	0
All deaths (n=9,11,9,7 ,2,6,4,4,6,7)	4	1	2	0	2	1	3	3	0	1

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w	**DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w**	**DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W**	**DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w**	**DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w**	**DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w**	**DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W**	**DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W**
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartaliz	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD +	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD +	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD +

	QD + TNO1 55 20 mg QD 3w/1w ; 28-day cycles.	QD + TNO1 55 20 mg QD 3w/1w ; 28-day cycles.	QD + TNO1 55 40 mg QD 3w/1w ; 28-day cycles.	QD + TNO1 55 40 mg QD 2w/1w ; 21-day cycles.	QD + TNO1 55 40 mg QD 2w/1w ; 21-day cycles.	umab 400 mg Q4W; 28-day cycles.	QD + TNO1 55 20 mg QD 3w/1w ; 28-day cycles.	QD + TNO1 55 20 mg QD 3w/1w ; 28-day cycles.	QD + TNO1 55 20 mg QD 2w/1w ; 21-day cycles.	QD + TNO1 55 40 mg QD 2w/1w ; 21-day cycles.	QD + TNO1 55 20 mg QD 2w/1w ; 21-day cycles.	tislelizumab 300 mg Q4W; 28-day cycles.	tislelizumab 300 mg Q4W; 28-day cycles.	tislelizumab 300 mg Q4W; 28-day cycles.
Number of Participants Analyzed [units: participants]	4	4	4	4	4	5	3	6	4	4	4	2	5	4
On-treatment and post-treatment safety FU deaths (n=4,4,4,4,4,5,3,6, 4,4,4,2,5,4)	0	0	0	0	1	3	0	0	1	0	0	1	2	2
Disease progression FU deaths (n=4,4,4,4,3,2,3,6, 3,4,4,1,3,2)	0	1	1	0	1	1	1	2	1	1	0	0	0	1
All deaths (n=4,4,4,4,4,5,3,6, 4,4,4,2,5,4)	0	1	1	0	2	4	1	2	2	1	0	1	2	3

Safety Results

Time Frame

On- and post-treatment safety FU: from the first dose of study treatment through 30 days after the last dose of dabrafenib, LTT462, trametinib, LXH254, or TNO155; 150 days after the last dose of spartalizumab; and 120 days after the last dose of tislelizumab, whichever was longer, up to maximum 90 weeks.

Deaths in disease progression FU period: after completing safety FU until end of study, up to maximum 90 weeks.

Source Vocabulary for Table Default	MedDRA (27.1)
Collection Approach for Table Default	Systematic Assessment

All-Cause Mortality

Safety FU - Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD N = 9	DRB436 150mg BID + LTT462 200mg QD N = 11	DRB436 150mg BID + LTT462 250mg QD N = 9	DRB436 150mg BID + LTT462 300mg QD N = 7	DRB436 150mg BID + LTT462 400mg QD N = 2	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD N = 6	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD N = 4	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD N = 4	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD N = 6	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID N = 7
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Total Number Affected	2	0	1	0	1	1	1	1	0	1
Total Number At Risk	9	11	9	7	2	6	4	4	6	7

Safety FU - Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w N = 4	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w N = 4	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w N = 4	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w N = 4	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w N = 4	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W N = 5	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w N = 3	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w N = 6	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w N = 4	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w N = 4	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w N = 4	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W N = 2	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W N = 5	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W N = 4
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Total Number Affected	0	0	0	0	1	3	0	0	1	0	0	1	2	2
Total Number At Risk	4	4	4	4	4	5	3	6	4	4	4	2	5	4

Disease Progression FU - Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD_Disease Progression FU period N = 7	DRB436 150mg BID + LTT462 200mg QD_ Disease Progression FU period N = 11	DRB436 150mg BID + LTT462 250mg QD_ Disease Progression FU period N = 8	DRB436 150mg BID + LTT462 300mg QD_ Disease Progression FU period N = 7	DRB436 150mg BID + LTT462 400mg QD_ Disease Progression FU period N = 1	DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD_ Disease Progression FU period N = 5	DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD_ Disease Progression FU period N = 3	DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD_ Disease Progression FU period N = 3	DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD_ Disease Progression FU period N = 6	DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID_ Disease Progression FU period N = 6
Arm/Group Description	Backbone Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Backbone Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Backbone Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Backbone Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Backbone Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Triplet Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Triplet Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Triplet Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Triplet Arm 1: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.	Triplet Arm 2: Deaths collected in the disease progression follow-up period. No AEs were collected during this period.
Total Number Affected	2	1	1	0	1	0	2	2	0	0
Total Number At Risk	7	11	8	7	1	5	3	3	6	6

Disease Progression FU - Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

	DRB436 150mg BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w_ Disease Progression FU period N = 4	DRB436 150mg BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w_ Disease Progression FU period N = 4	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w_ Disease Progression FU period N = 4	DRB436 150mg BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w_ Disease Progression FU period N = 4	DRB436 150mg BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w_ Disease Progression FU period N = 3	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg Q4W_ Disease Progression FU period N = 4	DRB436 150mg BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w_ Disease Progression FU period N = 3	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w_ Disease Progression FU period N = 6	DRB436 150mg BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w_ Disease Progression FU period N = 3	DRB436 150mg BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w_ Disease Progression FU period N = 4	DRB436 150mg BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w_ Disease Progression FU period N = 4	DRB436 100mg BID + LTT462 100mg QD + VDT482 300mg Q4W_ Disease Progression FU period N = 2	DRB436 150mg BID + LTT462 100mg QD + VDT482 300mg Q4W_ Disease Progression FU period N = 5	DRB436 150mg BID + LTT462 200mg QD + VDT482 300mg Q4W_ Disease Progression FU period N = 4
Arm/Group Description	Triplet Arm 3: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 3: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 3: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 3: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 3: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 4: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 5: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 5: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 5: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 5: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 5: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 6: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 6: Deaths collected in the disease progression follow-up period. No AEs were collected during this period	Triplet Arm 6: Deaths collected in the disease progression follow-up period. No AEs were collected during this period
Total Number	0	1	1	0	1	1	1	2	1	1	0	0	0	1

Affected														
Total Number At Risk	4	4	4	4	3	4	3	6	3	4	4	2	5	4

Serious Adverse Events

Time Frame	On- and post-treatment safety FU: from the first dose of study treatment through 30 days after the last dose of dabrafenib, LTT462, trametinib, LXH254, or TNO155; 150 days after the last dose of spartalizumab; and 120 days after the last dose of tislelizumab, whichever was longer, up to maximum 90 weeks.
Source Vocabulary for Table Default	MedDRA (27.1)
Collection Approach for Table Default	Systematic Assessment

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD N = 9	**DRB436 150mg BID + LTT462 200mg QD N = 11**	**DRB436 150mg BID + LTT462 250mg QD N = 9**	**DRB436 150mg BID + LTT462 300mg QD N = 7**	**DRB436 150mg BID + LTT462 400mg QD N = 2**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD N = 6**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD N = 4**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD N = 4**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD N = 6**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID N = 7**

Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD; 28-day cycles.	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-day cycles.
Total # Affected by any Serious Adverse Event	4	3	6	3	2	2	2	2	3	3
Total # at Risk by any Serious Adverse Event	9	11	9	7	2	6	4	4	6	7
Blood and lymphatic system disorders										
Anaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gastrointestinal disorders										
Abdominal pain	0 (0.00%)	0 (0.00%)	2 (22.22%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (16.67%)	1 (14.29%)
Diarrhoea	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Duodenal ulcer	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Ileus	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Intestinal obstruction	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Large intestine perforation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pancreatitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Small intestinal obstruction	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vomiting	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
General disorders and administration site conditions										
Asthenia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Fatigue	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Gait disturbance	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
General physical health deterioration	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Pyrexia	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	2 (33.33%)	0 (0.00%)
Sudden death	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Hepatobiliary disorders										
Hyperbilirubinaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypertransaminasaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Subcapsular hepatic haematoma	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Infections and infestations										
Abdominal infection	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bacteraemia	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Cellulitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Device related infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Ophthalmic herpes simplex	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pneumonia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Staphylococcal infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Injury, poisoning and procedural complications										
Procedural complication	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Investigations										
Amylase increased	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Blood bilirubin increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Lipase increased	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Metabolism and nutrition disorders										
Failure to thrive	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypokalaemia	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hyponatraemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Musculoskeletal and connective tissue disorders										
Back pain	2 (22.22%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)										
Tumour pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nervous system disorders										
Brain oedema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Cerebrovascular accident	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Epilepsy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hydrocephalus	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Peripheral motor neuropathy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Spinal cord compression	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Syncope	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Psychiatric disorders										
Confusional state	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Renal and urinary disorders										
Calculus urinary	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Chronic kidney disease	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Haematuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Renal failure	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Renal impairment	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Urinary bladder haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Respiratory, thoracic and mediastinal disorders										
Bronchospasm	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dyspnoea	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pleural effusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Productive cough	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pulmonary embolism	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin and subcutaneous tissue disorders										
Rash pruritic	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vascular disorders										
Hypotension	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

DRB436 150mg BID + LTT462 100mg QD + TNO155	DRB436 150mg BID + LTT462 200mg QD + TNO155	DRB436 150mg BID + LTT462 100mg QD + TNO155	DRB436 150mg BID + LTT462 100mg QD + TNO155	DRB436 150mg BID + LTT462 200mg QD + TNO155	DRB436 150mg BID + LTT462 100mg QD + PDR001 400mg	DRB436 150mg BID + TMT212 0.5mg QD +	DRB436 150mg BID + TMT212 1mg QD + TNO155	DRB436 150mg BID + TMT212 1mg QD + TNO155	DRB436 150mg BID + TMT212 1mg QD + TNO155	DRB436 150mg BID + TMT212 2mg QD + TNO155	DRB436 100mg BID + LTT462 100mg QD + VDT48	DRB436 150mg BID + LTT462 100mg QD + VDT48	DRB436 150mg BID + LTT462 200mg QD + VDT48

	55 20mg QD 3w/1w N = 4	55 20mg QD 3w/1w N = 4	55 40mg QD 3w/1w N = 4	55 40mg QD 2w/1w N = 4	55 40mg QD 2w/1w N = 4	Q4W N = 5	TNO1 55 20mg QD 3w/1w N = 3	20mg QD 3w/1w N = 6	20mg QD 2w/1w N = 4	40mg QD 2w/1w N = 4	20mg QD 2w/1w N = 4	2 300mg Q4W N = 2	2 300mg Q4W N = 5	2 300mg Q4W N = 4
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO1 55 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO1 55 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO1 55 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO1 55 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO1 55 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO1 55 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO1 55 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO1 55 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO1 55 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO1 55 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Total # Affected by any Serious Adverse Event	1	2	1	1	3	3	0	4	1	3	2	1	3	2
Total # at Risk by any Serious Adverse Event	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Blood and lymphatic system disorders														
Anaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)

Gastrointestinal disorders														
Abdominal pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Diarrhoea	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Duodenal ulcer	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Ileus	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Intestinal obstruction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Large intestine perforation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Pancreatitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Small intestinal obstruction	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vomiting	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
General disorders and administration site conditions														
Asthenia	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Fatigue	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gait disturbance	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
General physical health deterioration	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Pyrexia	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	1 (20.0 0%)	0 (0.00 %)
Sudden death	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hepatobiliary disorders														
Hyperbilirubinaemia	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Hypertransaminasaemia	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Subcapsular hepatic haematoma	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Infections and infestations														
Abdominal infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Bacteraemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Cellulitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Device related infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Ophthalmic herpes simplex	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pneumonia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Staphylococcal infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Injury, poisoning and procedural complications														

Procedural complication	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Investigations														
Amylase increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Blood bilirubin increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Lipase increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Metabolism and nutrition disorders														
Failure to thrive	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypokalaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hyponatraemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Musculoskeletal and connective tissue disorders														
Back pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)														
Tumour pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Nervous system disorders														

Brain oedema	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Cerebrovascular accident	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Epilepsy	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hydrocephalus	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Peripheral motor neuropathy	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Spinal cord compression	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Syncope	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Psychiatric disorders														
Confusional state	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Renal and urinary disorders														
Calculus urinary	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Chronic kidney disease	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Haematuria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Renal failure	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Renal impairment	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Urinary bladder haemorrhage	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Respiratory, thoracic and mediastinal disorders														
Bronchospasm	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Dyspnoea	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pleural effusion	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Productive cough	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pulmonary embolism	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Skin and subcutaneous tissue disorders														
Rash pruritic	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vascular disorders														
Hypotension	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00%)	0 (0.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)

Other (Not Including Serious) Adverse Events

Time Frame	On- and post-treatment safety FU: from the first dose of study treatment through 30 days after the last dose of dabrafenib, LTT462, trametinib, LXH254, or TNO155; 150 days after the last dose of spartalizumab; and 120 days after the last dose of tislelizumab, whichever was longer, up to maximum 90 weeks.
Source Vocabulary for Table Default	MedDRA (27.1)
Collection Approach for Table Default	Systematic Assessment
Frequent Event Reporting Threshold	5%

Backbone Arm 1, Triplet Arm 1 and Triplet Arm 2

	DRB436 150mg BID + LTT462 100mg QD N = 9	**DRB436 150mg BID + LTT462 200mg QD N = 11**	**DRB436 150mg BID + LTT462 250mg QD N = 9**	**DRB436 150mg BID + LTT462 300mg QD N = 7**	**DRB436 150mg BID + LTT462 400mg QD N = 2**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 1mg QD N = 6**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 1mg QD N = 4**	**DRB436 150mg BID + LTT462 100mg QD + TMT212 2mg QD N = 4**	**DRB436 150mg BID + LTT462 200mg QD + TMT212 2mg QD N = 6**	**DRB436 75mg BID + LTT462 100mg QD + LXH254 200mg BID N = 7**
Arm/Group Description	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 250 mg QD; 28-day cycles.	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 300 mg QD; 28-day cycles	Backbone Arm 1: dabrafenib 150 mg BID + LTT462 400 mg QD; 28-day cycles.	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 1 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 1 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 100 mg QD + trametinib 2 mg QD;	Triplet Arm 1: dabrafenib 150 mg BID + LTT462 200 mg QD + trametinib 2 mg QD;	Triplet Arm 2: dabrafenib 75 mg BID + LTT462 100 mg QD + LXH254 200 mg BID; 28-

						28-day cycles.	28-day cycles.	28-day cycles.	28-day cycles.	day cycles.
Total # Affected by any Other Adverse Event	9	11	9	7	2	6	4	4	6	7
Total # at Risk by any Other Adverse Event	9	11	9	7	2	6	4	4	6	7
Blood and lymphatic system disorders										
Anaemia	0 (0.00%)	1 (9.09%)	3 (33.33%)	2 (28.57%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (50.00%)	2 (33.33%)	0 (0.00%)
Lymphopenia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Neutropenia	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Thrombocytopenia	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Cardiac disorders										
Bundle branch block left	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Left ventricular dysfunction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Palpitations	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Sinus bradycardia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Sinus tachycardia	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tachycardia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Ear and labyrinth disorders										
Ear pain	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Eustachian tube obstruction	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tinnitus	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vertigo	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Endocrine disorders										
Adrenal insufficiency	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypothyroidism	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Thyroiditis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Eye disorders										
Blepharitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Central vision loss	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Corneal epithelium defect	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dry eye	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Eye disorder	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Eye haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Eye pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Eyelid oedema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Eyelid pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Foreign body sensation in eyes	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Keratitis	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Lens disorder	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Periorbital oedema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Retinal vascular disorder	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Retinal vein occlusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Retinopathy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Subretinal fluid	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Uveitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vision blurred	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Visual field defect	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Visual impairment	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vitreous detachment	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gastrointestinal disorders										
Abdominal discomfort	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Abdominal distension	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	1 (14.29%)
Abdominal hernia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Abdominal pain	2 (22.22%)	1 (9.09%)	4 (44.44%)	4 (57.14%)	2 (100.00%)	3 (50.00%)	3 (75.00%)	0 (0.00%)	3 (50.00%)	1 (14.29%)
Abdominal pain lower	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Abdominal pain upper	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (28.57%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)

Anal incontinence	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Anal inflammation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Aphthous ulcer	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Ascites	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Cheilitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Constipation	0 (0.00%)	0 (0.00%)	2 (22.22%)	3 (42.86%)	1 (50.00%)	1 (16.67%)	0 (0.00%)	2 (50.00%)	0 (0.00%)	1 (14.29%)
Diarrhoea	1 (11.11%)	7 (63.64%)	3 (33.33%)	2 (28.57%)	2 (100.00%)	4 (66.67%)	3 (75.00%)	1 (25.00%)	6 (100.00%)	2 (28.57%)
Dry mouth	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	2 (50.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Dyspepsia	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Dysphagia	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Faecaloma	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Flatulence	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gastric ulcer	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Gastrointestinal pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gastrooesophageal reflux disease	0 (0.00%)	0 (0.00%)	1 (11.11%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Gingival bleeding	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Haematochezia	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Haemorrhoids	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Intestinal obstruction	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Large intestine perforation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nausea	5 (55.56%)	4 (36.36%)	4 (44.44%)	3 (42.86%)	1 (50.00%)	5 (83.33%)	1 (25.00%)	2 (50.00%)	4 (66.67%)	2 (28.57%)
Odynophagia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oesophageal pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oesophageal spasm	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Rectal discharge	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Rectal haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Salivary hypersecretion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Stomatitis	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Subileus	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tongue discomfort	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Toothache	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Umbilical hernia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vomiting	3 (33.33%)	3 (27.27%)	2 (22.22%)	4 (57.14%)	1 (50.00%)	3 (50.00%)	1 (25.00%)	1 (25.00%)	4 (66.67%)	1 (14.29%)
General disorders and administration site conditions										
Asthenia	2 (22.22%)	1 (9.09%)	1 (11.11%)	2 (28.57%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (28.57%)
Chills	1 (11.11%)	0 (0.00%)	1 (11.11%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	1 (25.00%)	1 (16.67%)	1 (14.29%)

Cyst	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Face oedema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Fatigue	2 (22.22%)	2 (18.18%)	3 (33.33%)	4 (57.14%)	1 (50.00%)	1 (16.67%)	1 (25.00%)	3 (75.00%)	4 (66.67%)	3 (42.86%)
Feeling abnormal	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gait disturbance	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Influenza like illness	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Localised oedema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Malaise	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Mucosal inflammation	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Non-cardiac chest pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oedema peripheral	1 (11.11%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	1 (14.29%)
Pain	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pyrexia	3 (33.33%)	5 (45.45%)	5 (55.56%)	3 (42.86%)	1 (50.00%)	5 (83.33%)	2 (50.00%)	3 (75.00%)	4 (66.67%)	1 (14.29%)
Thirst decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hepatobiliary disorders										
Hepatic pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Hyperbilirubinaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypertransaminasaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Jaundice	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Portal vein thrombosis	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Immune system disorders										
Drug hypersensitivity	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypersensitivity	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Infections and infestations										
Abdominal wall abscess	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bacteriuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Body tinea	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bronchitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Conjunctivitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
COVID-19	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Cystitis	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Gastroenteritis viral	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Haematological infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Influenza	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nasopharyngitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Oral candidiasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oral herpes	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Periumbilical abscess	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Rash pustular	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Subcutaneous abscess	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tongue fungal infection	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tooth abscess	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Upper respiratory tract infection	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Urinary tract infection	0 (0.00%)	1 (9.09%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Injury, poisoning and procedural complications										
Immunisation reaction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Infusion related reaction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Post procedural discomfort	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Post procedural haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Procedural pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tendon rupture	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Toxicity to various agents	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Investigations										
Alanine aminotransferase increased	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (14.29%)

Amylase increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Aspartate aminotransferase increased	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (50.00%)	1 (16.67%)	1 (14.29%)
Blood alkaline phosphatase increased	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Blood bilirubin increased	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Blood cholesterol increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Blood creatine phosphokinase increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	2 (33.33%)	0 (0.00%)
Blood creatinine increased	0 (0.00%)	1 (9.09%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Blood magnesium decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Blood thyroid stimulating hormone increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Brain natriuretic peptide increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
C-reactive protein increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Ejection fraction decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gamma-glutamyltransferase increased	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Glomerular filtration rate decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Inflammatory marker increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Lipase increased	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (100.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	2 (28.57%)
Lymphocyte count decreased	0 (0.00%)	1 (9.09%)	1 (11.11%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Neutrophil count decreased	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (33.33%)	0 (0.00%)	1 (25.00%)	1 (16.67%)	0 (0.00%)
N-terminal prohormone brain natriuretic peptide increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Platelet count decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Prohormone brain natriuretic peptide increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
SARS-CoV-2 test positive	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Troponin T increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Weight decreased	2 (22.22%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	2 (50.00%)	1 (16.67%)	0 (0.00%)
Weight increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
White blood cell count decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Metabolism and nutrition disorders										
Decreased appetite	2 (22.22%)	3 (27.27%)	3 (33.33%)	4 (57.14%)	1 (50.00%)	1 (16.67%)	1 (25.00%)	2 (50.00%)	3 (50.00%)	2 (28.57%)
Dehydration	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (14.29%)

Diabetic metabolic decompensation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypercalcaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hyperglycaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypoalbuminaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Hypocalcaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypokalaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	1 (14.29%)
Hypomagnesaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hyponatraemia	1 (11.11%)	1 (9.09%)	2 (22.22%)	1 (14.29%)	1 (50.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (14.29%)
Hypophosphataemia	0 (0.00%)	1 (9.09%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Hypoproteinaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Hypovolaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Iron deficiency	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Polydipsia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Musculoskeletal and connective tissue disorders										
Arthralgia	2 (22.22%)	4 (36.36%)	2 (22.22%)	3 (42.86%)	0 (0.00%)	2 (33.33%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	1 (14.29%)
Arthritis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Back pain	2 (22.22%)	3 (27.27%)	1 (11.11%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	2 (28.57%)

Flank pain	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Groin pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Joint stiffness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Mobility decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Muscle spasms	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Muscular weakness	0 (0.00%)	0 (0.00%)	1 (11.11%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Musculoskeletal chest pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Musculoskeletal stiffness	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Myalgia	0 (0.00%)	2 (18.18%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (16.67%)	2 (28.57%)
Neck pain	0 (0.00%)	0 (0.00%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pain in extremity	0 (0.00%)	2 (18.18%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	1 (14.29%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)										
Melanocytic naevus	1 (11.11%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Seborrhoeic keratosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin papilloma	0 (0.00%)	2 (18.18%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tumour pain	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)

Nervous system disorders										
Anosmia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dizziness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dysgeusia	0 (0.00%)	0 (0.00%)	2 (22.22%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Fine motor skill dysfunction	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Headache	3 (33.33%)	2 (18.18%)	2 (22.22%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	1 (25.00%)	1 (25.00%)	4 (66.67%)	1 (14.29%)
Hemianopia homonymous	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Hemiparesis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypoaesthesia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Memory impairment	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Neurotoxicity	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Paraesthesia	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Peripheral motor neuropathy	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Peripheral sensory neuropathy	0 (0.00%)	1 (9.09%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Restless legs syndrome	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Syncope	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Trigeminal neuralgia	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Psychiatric disorders										

Anxiety	0 (0.00%)	2 (18.18%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (50.00%)	0 (0.00%)	0 (0.00%)
Fear	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Insomnia	0 (0.00%)	0 (0.00%)	1 (11.11%)	3 (42.86%)	0 (0.00%)	1 (16.67%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Mental status changes	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nervousness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Personality change	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Restlessness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Renal and urinary disorders										
Acute kidney injury	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bladder pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bladder spasm	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Chromaturia	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Haematuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nocturia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oliguria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Pollakiuria	0 (0.00%)	1 (9.09%)	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Polyuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Proteinuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Urinary incontinence	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)

Urinary retention	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Reproductive system and breast disorders										
Erectile dysfunction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Vaginal haemorrhage	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Respiratory, thoracic and mediastinal disorders										
Cough	0 (0.00%)	2 (18.18%)	2 (22.22%)	1 (14.29%)	1 (50.00%)	0 (0.00%)	1 (25.00%)	2 (50.00%)	0 (0.00%)	0 (0.00%)
Dry throat	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Dysphonia	1 (11.11%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dyspnoea	1 (11.11%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Dyspnoea exertional	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Epistaxis	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (42.86%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Increased upper airway secretion	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nasal mucosal blistering	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oropharyngeal pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pleural effusion	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Pneumothorax	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Productive cough	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Pulmonary embolism	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Rhinorrhoea	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Sneezing	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin and subcutaneous tissue disorders										
Alopecia	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Dermatitis	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dermatitis acneiform	1 (11.11%)	1 (9.09%)	1 (11.11%)	1 (14.29%)	0 (0.00%)	1 (16.67%)	1 (25.00%)	0 (0.00%)	1 (16.67%)	2 (28.57%)
Dry skin	2 (22.22%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (33.33%)	0 (0.00%)
Ecchymosis	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Erythema	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hyperhidrosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hyperkeratosis	1 (11.11%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Night sweats	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Palmar-plantar erythrodysaesthesia syndrome	1 (11.11%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)
Papule	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pruritus	2 (22.22%)	3 (27.27%)	1 (11.11%)	2 (28.57%)	1 (50.00%)	2 (33.33%)	0 (0.00%)	0 (0.00%)	2 (33.33%)	1 (14.29%)

Rash	2 (22.22%)	0 (0.00%)	1 (11.11%)	2 (28.57%)	2 (100.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (16.67%)	1 (14.29%)
Rash maculo-papular	1 (11.11%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (16.67%)	0 (0.00%)
Rash pruritic	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Skin burning sensation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin hyperpigmentation	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin lesion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Skin mass	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Urticaria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vascular disorders										
Deep vein thrombosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)
Embolism	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Hot flush	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypertension	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)	0 (0.00%)	1 (16.67%)	0 (0.00%)
Hypotension	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (14.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Thrombosis	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Triplet Arm 3, Triplet Arm 4, Triplet Arm 5 and Triplet Arm 6

DRB436 150m	DRB436 150m	DRB436 150m	DRB436 150m	DRB436 150mg	DRB436 150mg BID +	DRB436 150m	DRB436 150m	DRB436 150m	DRB436 150m	DRB436 150mg	DRB436 100mg	DRB436 150mg	DRB436 150mg

	g BID + LTT462 100mg QD + TNO155 20mg QD 3w/1w N = 4	g BID + LTT462 200mg QD + TNO155 20mg QD 3w/1w N = 4	g BID + LTT462 100mg QD + TNO155 40mg QD 3w/1w N = 4	g BID + LTT462 100mg QD + TNO155 40mg QD 2w/1w N = 4	BID + LTT462 200mg QD + TNO155 40mg QD 2w/1w N = 4	LTT462 100mg QD + PDR001 400mg Q4W N = 5	g BID + TMT212 0.5mg QD + TNO155 20mg QD 3w/1w N = 3	g BID + TMT212 1mg QD + TNO155 20mg QD 3w/1w N = 6	g BID + TMT212 1mg QD + TNO155 20mg QD 2w/1w N = 4	g BID + TMT212 1mg QD + TNO155 40mg QD 2w/1w N = 4	BID + TMT212 2mg QD + TNO155 20mg QD 2w/1w N = 4	BID + LTT462 100mg QD + VDT482 300mg Q4W N = 2	BID + LTT462 100mg QD + VDT482 300mg Q4W N = 5	BID + LTT462 200mg QD + VDT482 300mg Q4W N = 4
Arm/Group Description	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 3w/1w; 28-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 100 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 3: dabrafenib 150 mg BID + LTT462 200 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 4: dabrafenib 150 mg BID + LTT462 100 mg QD + spartalizumab 400 mg Q4W; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 0.5 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 3w/1w; 28-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 1 mg QD + TNO155 40 mg QD 2w/1w; 21-day cycles.	Triplet Arm 5: dabrafenib 150 mg BID + trametinib 2 mg QD + TNO155 20 mg QD 2w/1w; 21-day cycles.	Triplet Arm 6: dabrafenib 100 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 100 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.	Triplet Arm 6: dabrafenib 150 mg BID + LTT462 200 mg QD + tislelizumab 300 mg Q4W; 28-day cycles.
Total # Affected by any Other Adverse Event	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Total # at Risk by any Other Adverse Event	4	4	4	4	4	5	3	6	4	4	4	2	5	4
Blood and lymphatic														

system disorders														
Anaemia	0 (0.00 %)	1 (25.0 0%)	2 (50.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	2 (33.3 3%)	1 (25.0 0%)	1 (25.0 0%)	2 (50.0 0%)	0 (0.00 %)	3 (60.0 0%)	3 (75.0 0%)
Lymphopenia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Neutropenia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Thrombocytopenia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Cardiac disorders														
Bundle branch block left	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Left ventricular dysfunction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Palpitations	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Sinus bradycardia	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Sinus tachycardia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Tachycardia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Ear and labyrinth disorders														
Ear pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Eustachian tube obstruction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Tinnitus	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vertigo	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Endocrine disorders														
Adrenal insufficiency	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Hypothyroidism	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Thyroiditis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Eye disorders														
Blepharitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Central vision loss	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Corneal epithelium defect	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dry eye	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Eye disorder	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Eye haemorrhage	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Eye pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Eyelid oedema	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)

Eyelid pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Foreign body sensation in eyes	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Keratitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Lens disorder	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Periorbital oedema	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Retinal vascular disorder	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Retinal vein occlusion	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Retinopathy	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Subretinal fluid	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Uveitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vision blurred	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Visual field defect	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Visual impairment	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vitreous detachment	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gastrointestinal disorders														

Abdominal discomfort	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Abdominal distension	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Abdominal hernia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Abdominal pain	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	2 (40.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	2 (50.0 0%)	1 (50.0 0%)	2 (40.0 0%)	0 (0.00 %)
Abdominal pain lower	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Abdominal pain upper	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Anal incontinence	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Anal inflammation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Aphthous ulcer	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Ascites	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Cheilitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Constipation	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	2 (50.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	2 (100. 00%)	0 (0.00 %)	0 (0.00 %)
Diarrhoea	1 (25.0 0%)	3 (75.0 0%)	2 (50.0 0%)	1 (25.0 0%)	1 (25.0 0%)	3 (60.00 %)	2 (66.6 7%)	3 (50.0 0%)	3 (75.0 0%)	3 (75.0 0%)	4 (100. 00%)	1 (50.0 0%)	2 (40.0 0%)	2 (50.0 0%)
Dry mouth	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dyspepsia	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dysphagia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Faecaloma	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Flatulence	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gastric ulcer	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gastrointestinal pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gastrooesophageal reflux disease	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gingival bleeding	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Haematochezia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Haemorrhoids	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Intestinal obstruction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Large intestine perforation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Nausea	0 (0.00 %)	1 (25.0 0%)	2 (50.0 0%)	3 (75.0 0%)	4 (100. 00%)	3 (60.00 %)	0 (0.00 %)	3 (50.0 0%)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	1 (50.0 0%)	2 (40.0 0%)	1 (25.0 0%)
Odynophagia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Oesophageal pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Oesophageal spasm	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Rectal discharge	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Rectal haemorrhage	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Salivary hypersecretion	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Stomatitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Subileus	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Tongue discomfort	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Toothache	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Umbilical hernia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vomiting	0 (0.00 %)	1 (25.0 0%)	3 (75.0 0%)	1 (25.0 0%)	2 (50.0 0%)	1 (20.00 %)	1 (33.3 3%)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	2 (50.0 0%)
General disorders and administration site conditions														
Asthenia	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	1 (25.0 0%)	2 (50.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)
Chills	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	2 (50.0 0%)	1 (25.0 0%)	2 (40.00 %)	1 (33.3 3%)	2 (33.3 3%)	1 (25.0 0%)	1 (25.0 0%)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Cyst	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Face oedema	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Fatigue	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)	3 (60.00 %)	0 (0.00 %)	3 (50.0 0%)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Feeling abnormal	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Gait disturbance	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Influenza like illness	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Localised oedema	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Malaise	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Mucosal inflammation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Non-cardiac chest pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Oedema peripheral	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	1 (20.00 %)	1 (33.3 3%)	1 (16.6 7%)	1 (25.0 0%)	3 (75.0 0%)	3 (75.0 0%)	0 (0.00 %)	2 (40.0 0%)	0 (0.00 %)
Pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Pyrexia	1 (25.0 0%)	0 (0.00 %)	2 (50.0 0%)	1 (25.0 0%)	0 (0.00 %)	3 (60.00 %)	1 (33.3 3%)	3 (50.0 0%)	3 (75.0 0%)	1 (25.0 0%)	1 (25.0 0%)	1 (50.0 0%)	3 (60.0 0%)	1 (25.0 0%)
Thirst decreased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hepatobiliary disorders														
Hepatic pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hyperbilirubinaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Hypertransaminasaemia	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Jaundice	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Portal vein thrombosis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Immune system disorders														
Drug hypersensitivity	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypersensitivity	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.67%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Infections and infestations														
Abdominal wall abscess	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Bacteriuria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00%)	0 (0.00 %)
Body tinea	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Bronchitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Conjunctivitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
COVID-19	0 (0.00 %)	1 (25.00%)	1 (25.00%)	1 (25.00%)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00%)	0 (0.00 %)
Cystitis	0 (0.00 %)	0 (0.00 %)	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Gastroenteritis viral	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Haematological infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Influenza	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.00%)
Nasopharyngitis	0 (0.00 %)	0 (0.00 %)	1 (25.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.67%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Oral candidiasis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Oral herpes	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Periumbilical abscess	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Rash pustular	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Skin infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Subcutaneous abscess	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Tongue fungal infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Tooth abscess	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Upper respiratory tract infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Urinary tract infection	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Injury, poisoning and procedural complications														
Immunisation reaction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Infusion related reaction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Post procedural discomfort	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Post procedural haemorrhage	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Procedural pain	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Tendon rupture	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Toxicity to various agents	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Investigations														
Alanine aminotransferase increased	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Amylase increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Aspartate aminotransferase increased	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	1 (16.6 7%)	2 (50.0 0%)	1 (25.0 0%)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Blood alkaline phosphatase increased	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Blood bilirubin increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (40.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Blood cholesterol increased	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Blood creatine phosphokinase increased	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Blood creatinine increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	2 (40.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Blood magnesium decreased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Blood thyroid stimulating hormone increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Brain natriuretic peptide increased	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
C-reactive protein increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Ejection fraction decreased	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (50.0 0%)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Gamma-glutamyltransferase increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Glomerular filtration rate decreased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Inflammatory marker increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Lipase increased	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Lymphocyte count decreased	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Neutrophil count decreased	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

N-terminal prohormone brain natriuretic peptide increased	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Platelet count decreased	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Prohormone brain natriuretic peptide increased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
SARS-CoV-2 test positive	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Troponin T increased	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Weight decreased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (40.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (40.0 0%)	0 (0.00 %)
Weight increased	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
White blood cell count decreased	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Metabolism and nutrition disorders														
Decreased appetite	2 (50.0 0%)	0 (0.00 %)	2 (50.0 0%)	1 (25.0 0%)	2 (50.0 0%)	2 (40.00 %)	0 (0.00 %)	2 (33.3 3%)	1 (25.0 0%)	2 (50.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Dehydration	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Diabetic metabolic decompensation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Hypercalcaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hyperglycaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypoalbuminaemia	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Hypocalcaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Hypokalaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	2 (50.0 0%)
Hypomagnesaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hyponatraemia	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Hypophosphataemia	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypoproteinaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypovolaemia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Iron deficiency	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Polydipsia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Musculoskeletal and connective tissue disorders														
Arthralgia	0 (0.00 %)	2 (50.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	2 (40.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	2 (50.0 0%)
Arthritis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)

Back pain	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Flank pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Groin pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Joint stiffness	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Mobility decreased	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Muscle spasms	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (40.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Muscular weakness	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Musculoskeletal chest pain	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Musculoskeletal stiffness	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Myalgia	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Neck pain	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pain in extremity	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	1 (25.0 0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)														
Melanocytic naevus	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)

Seborrhoeic keratosis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Skin papilloma	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Tumour pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Nervous system disorders														
Anosmia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dizziness	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dysgeusia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Fine motor skill dysfunction	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Headache	0 (0.00 %)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	2 (50.0 0%)
Hemianopia homonymous	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hemiparesis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypoaesthesia	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Memory impairment	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Neurotoxicity	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Paraesthesia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Peripheral motor neuropathy	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Peripheral sensory neuropathy	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Restless legs syndrome	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Syncope	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Trigeminal neuralgia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Psychiatric disorders														
Anxiety	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Fear	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Insomnia	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Mental status changes	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Nervousness	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Personality change	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Restlessness	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Renal and urinary disorders														
Acute kidney injury	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)

Bladder pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Bladder spasm	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (50.0 0%)	0 (0.00 %)	0 (0.00 %)
Chromaturia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Haematuria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Nocturia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Oliguria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pollakiuria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Polyuria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Proteinuria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Urinary incontinence	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Urinary retention	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Reproductive system and breast disorders														
Erectile dysfunction	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Vaginal haemorrhage	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Respiratory, thoracic and														

mediastinal disorders														
Cough	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Dry throat	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dysphonia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dyspnoea	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.0 0%)	0 (0.00 %)
Dyspnoea exertional	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Epistaxis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Increased upper airway secretion	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Nasal mucosal blistering	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Oropharyngeal pain	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pleural effusion	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pneumothorax	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Productive cough	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pulmonary embolism	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Rhinorrhoea	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Sneezing	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Skin and subcutaneous tissue disorders														
Alopecia	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dermatitis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Dermatitis acneiform	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	2 (50.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Dry skin	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Ecchymosis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Erythema	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hyperhidrosis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hyperkeratosis	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Night sweats	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Palmar-plantar erythrodysaesthesia syndrome	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Papule	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Pruritus	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (50.0 0%)	1 (20.0 0%)	2 (50.0 0%)

Rash	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (20.0 0%)	2 (50.0 0%)
Rash maculo-papular	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Rash pruritic	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Skin burning sensation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Skin hyperpigmentation	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Skin lesion	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Skin mass	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Urticaria	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (16.6 7%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)
Vascular disorders														
Deep vein thrombosis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Embolism	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hot flush	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypertension	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	1 (33.3 3%)	0 (0.00 %)	1 (25.0 0%)	1 (25.0 0%)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Hypotension	0 (0.00 %)	0 (0.00 %)	1 (25.0 0%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	2 (40.0 0%)	0 (0.00 %)
Thrombosis	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)

Conclusion:

The study was terminated early due to strategic reasons related to the program, and not because of any safety concern. The RD was not declared for any of the treatment arms.

The safety profile was well characterized in all treatment arms evaluated in this study. Overall, the doses and combinations explored were manageable and no potential safety concerns were identified.

The PK of each combination therapy was generally consistent with those observed for the individual drugs, with no clear evidence of pharmacokinetic drug-drug interactions involving DRB436 when combined with other treatment partners. However, these findings should be interpreted cautiously due to the limited data available.

Modest antitumor effect was demonstrated in all treatment arms evaluated in the study, however, due to limited data, no definitive conclusion could be drawn on efficacy for any of the individual treatment arms.

Date of Clinical Trial Report

23-Jun-2025